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Ghrelin, a 28-amino acid peptide, is identified as the endogenous ligand of the 
orphan growth hormone secretagogue-receptor type 1a. Ghrelin presents a unique 
modification at Ser3 position essential for its activity. It was first discovered in the 
stomach of rat in 1999.  Aside from ghrelin’s role as a potent growth hormone 
secretagogue and food intake modulator, ghrelin is thought to play a role in insulin 
and glucagon secretion and in glucose homeostasis. A lot of contradictory data have 
been reported in the literature regarding ghrelins co-localization with other hormones 
in the islets of Langerhans, its role in insulin secretion and attenuation of type 2 
diabetes mellitus. In this study, we investigated the effect of chronic ghrelin 
treatment on glucose, body weight and insulin level in normal, STZ-induced diabetic 
and ghrelin-treated male Wistar rats. We also examined the distribution pattern and 
co-localization of ghrelin in the pancreatic islet of Langerhans with both pancreatic 
hormones; insulin and glucagon. In addition, we examined how ghrelin treatment 
influences liver function in normal and STZ-diabetic Wistar rats. Control groups 
received intraperitoneal injection of normal saline while treated groups received 
intraperitoneal injections of 5µg/kg ghrelin on daily basis for duration of four weeks. 
Our results show that administration of ghrelin increases the serum insulin level in 
both normal and diabetic rats. We also demonstrated that ghrelin co-localizes with 
insulin as well as glucagon in the pancreatic islet cells and that the pattern of ghrelin 
distribution is shown to alter after the onset of diabetes. Moreover, ghrelin treatment 
increased insulin secretion as a result of increasing insulin-secreting β cells. In 
conclusion ghrelin co-localizes with both insulin and glucagon in pancreatic islet 
cells and plays a regulatory role in insulin secretion. 
 
Keywords: Ghrelin, diabetes mellitus, streptozotocin (STZ), immunohistochemistry 







Title and Abstract (in Arabic) 
 
في خاليا جزر البنكرياس في الجرذان المصابة بالسكري و  (ghrelin) توزيع الجريلين
 السليمة غير المصابة و تأثيره على مرض السكري
 الملخص
 حمض أميني، تم 82( هرمون يفرز من المعدة ويتكون من ghrelinالجريلين )
يتميز الجريلين بخاصية تعديل   .على أنه محفز قوي الفراز هرمون النمو 9111اكتشافه عام 
بمستقبالت الذي يرتبط بدوره  ( ليتحول إلى شكله النشطSer3حمضه األميني الثالث سيرين )
ليقوم بلعب دوره في افراز هرمون النمو و  (a1 (GHS-R 1aافراز هرمون النمو من نوع 
كافة األنشطة األخرى المعروفة عنه. من جهة أخرى، يظن دوره كهرمون منظم للشهية و 
الباحثون أن الجريلين يلعب دور في افراز هرمون االنسولين و الجلوكاجون و أيضا في تعديل 
 مستويات السكر في الدم. 
درته نظراً الختلف الباحثين بخصوص تأثير الجريلين على افراز هرمون االنسولين وق
حول تواجد الجريلين في  ج األبحاثئلثاني ، و تعارض نتاالنوع امن  مرض السكرعلى تحسين 
قمنا  خاليا بيتا المفرزة لالنسولين و خاليا ألفا المفرزة للجلوكاجون في جزر البنكرياس. 
غير   Wistarبتصميم هذه الدراسة للبحث عن تأثير العالج بالجريلين على جرذان من نوع 
 Streptozotocinستريبتوزوتوسين ) ابين بالسكر و مقارنتهم بآخرين تم حقنهم بمادةالمص
“STZ” )  مرض السكر لدى القوارض و غيرها.بللتسبب  األبحاثالتي تستخدم في  
جرذان تمت مجموعة أخرى من الكما تمت مقارنة نتائج العالج بالجريلين بنتائج 
 5تم خاللها حقن أسابيع من العالج  4بعد  (Normal Salineمعالجتهم بمحلول ملحي )






يكمن الهدف  من هذه األطروحة في الكشف عن دور الجريلين كعالج لمرض السكر، 
بالدم وقدرته على افراز حيث تقوم الدراسة بعرض تأثير العالج بالجريلين على مستويات السكر 
االنسولين ومدى تأثيره على الوزن نظراً لكونه هرمون فاتح للشهية. كما تمت دراسة تأثير 
 . الكبدالعالج بالجريلين على وضائف 
في  هباإلضافة إلى ذلك، تمت دراسة نمط توزيع الجريلين في جزر البنكرياس وتواجد
 المفرزة لهرمون الجلوكاجون. ألفايا خالو  المفرزة لهرمون االنسولين خاليا بيتا
كشف البحث عن تواجد الجيريلين في خاليا بيتا و ألفا على حد سواء حيث يختلف 
التوزيع نسبيا بعد االصابة بمرض السكر. كما أثبتت الدراسة قدرت العالج بالجريلين على 
نسولين في جزر زيادة نسبة االنسولين في الدم؛ كنتيجة لزيادة عدد الخاليا المفرزة لال
 البنكرياس.
 
(، مرض السكر، ستريبتوزوتوسين Ghrelinالجريلين) مفاهيم البحث الرئيسية:
(Streptozotocin “STZ”اختبار المناعه الكيمونسيجية ،)  (Immunohistochemistry 









In the name of Allah, most gracious and most merciful. Praise be to Allah, 
Lord of the worlds for blessing me with the strength and patience I needed to go 
through this journey, and for surrounding me with amazing people who helped me 
through difficult times and stood with me every time I felt like giving up.  
Foremost, I would like to express my sincere gratitude to Prof. Ernest 
Adeghate for the continuous support of my MSc study and research and for his 
understanding and encouragement. 
I would also like to thank the members of my thesis committee; Prof. Abdu 
Adem and Prof. Frank C. Howarth, for their encouragement and insightful 
comments. 
My sincere thanks also go to my external examiner Prof. Masayasu Kojima, 
for his motivational comments, enthusiasm and most of all for being an inspiration.  
I am also grateful to Mr. Rasheed Hameed and Mrs. Crystal Melanie 
D'Souza. I am extremely thankful to both of them for their sincere help, guidance and 
constant encouragement.  
I would like to take this opportunity to express gratitude to my family for the 
endless encouragement, unconditional love and support, prayers and patience, and 
for their understanding. I am grateful to have such a loving family who supported my 
ambitions by believing in me.  
I am also immensely grateful to my best friends Rana, Safa and Reem 
FarajAllah for their love, care and ultimate support and encouragement. I am blessed 
to have them in my life. They made me laugh and forget my troubles so I couldn’t 






Thanks to my dearest friend Amal who was always there for me in every step 
of this journey. Thanks for really helping me when I needed it the most. Thank you 
to my lovely friend Salma, for her constant encouragement and her confidence in me. 
Thanks to Rawan for being a sister at heart, for the sweet memories we shared 
together and for just being amazing. Finally I would like to thank Deena for her 
















































Table of Contents 
 
Title………………………………………………………………………………….i 
Declaration of Original Work………………………………………………………ii 
Copyright…………………………………………………………………………...iii 
Approval of the Master Thesis...…………………………………………………...iv 
Abstract……………………………………………………………………………..vi 
Title and Abstract (in Arabic)………………………………………….……….…vii 
Acknowledgements………………………………………………………………...ix 
Dedication…………………………………………………………………………..xi 
Table of Contents………………………………………………………………….xii 
List of Tables…………………………………………………………………..…xvii 
List of Figures……………..……………………………………………..…...…xviii 
Chapter 1: Introduction……………………………………………………………...1 
1.1   Pancreas………………………………………………………………..1 
1.1.1   Exocrine Part of the Pancreas……………………………………...3 
1.1.2   Endocrine Part of the Pancreas…………………………………….4 
1.1.3   Hormones of the Pancreas………………………………………....5 
1.1.3.1   Insulin…………………………………….................................5 
1.1.3.1.1   Discovery of Insulin………………….................................6 
1.1.3.1.2   Synthesis of Insulin……….………….................................8 
1.1.3.1.3   Function of Insulin…………………....................................9 
1.1.3.1.4   Receptors of Insulin……………………..............................9 
1.1.3.1.5   Mechanism of Action Insulin……………….....................10 
1.1.3.2   Glucagon……………………………………...........................11 






1.1.3.4   Pancreatic Polypeptide...……………………..........................12 
1.1.4   Diseases of the Pancreas……………………………………….....12 
1.2   Diabetes Mellitus……………………………………………………..13 
1.2.1   History of Diabetes Mellitus……………………………………...13 
1.2.2   Epidemiology and Prevalence of Diabetes Mellitus……………...14 
1.2.3   Definition of Diabetes Mellitus…...……………………………...15 
1.2.4   Classifications of Diabetes Mellitus……………………………...15 
1.2.4.1   Type 1 Diabetes Mellitus.………………………….................16 
1.2.4.2   Type 2 Diabetes Mellitus.………………………….................17 
1.2.4.3   Gestational Diabetes Mellitus.……………….…….................17 
1.2.4.4   Other Types of Diabetes Mellitus.……………….……...........18 
1.2.5   Symptoms of Diabetes Mellitus.….……………………………...18 
1.2.6   Criteria for Diagnosis of Diabetes Mellitus.….…………………..20 
1.2.7   Complications of Diabetes Mellitus.….…..……………………...20 
1.2.8   Management and Treatment of Diabetes Mellitus.….…………...22 
1.2.8.1   Nutrition.…………………………...........................................22 
1.2.8.2   Exercise.…………………………...........................................23 
1.2.8.3   Pharmacotherapy…………....……………….…….................24 
1.2.8.3.1   Insulin Treatment of Diabetes Mellitus...…..….................24 
1.2.8.3.2   Oral Antidiabetic Agents……………..….…….................25 
1.2.8.3.2.1   Insulin Secretagogues…...….….....….…….................26 
1.2.8.3.2.2   Biguanids…...……….......……....................................27 
1.2.8.3.2.3   Thiazolidinediones or Glitazones.................................27 
1.2.8.3.2.4   α-Glucosidase Inhibitors.….…….................................28 
1.2.8.3.2.5   Other Antidiabetic Agents...…….................................28 






1.2.8.4.1   Islet and Pancreatic Transplantation…......…….................30 
1.2.8.4.2   Other Types of Treatments…………......….……..............31 
1.2.8.4.3   Glucagon-like Peptide-1……………......….……..............31 
1.2.8.4.4   Leptin…………………………….…...….…….................32 
1.2.8.4.5   Substance P…………………………......……...................32 
1.2.8.4.6   Ghrelin……………………………......….…….................33 
1.3   Ghrelin ……………………………………………………………….34 
1.3.1   Discovery of Ghrelin……………...……………………………...34 
1.3.2   Structure of Ghrelin…………..…...……………………………...34 
1.3.3   Ghrelin Receptor…...………………………...…………………...35 
1.3.4   Tissue Distribution of Ghrelin…...……………………………….36 
1.3.5   Ghrelin Signaling Pathway…...…...……………………………...37 
1.3.6   Effect of Ghrelin on Food Intake.....……………………………...39 
1.3.7   Effect of Ghrelin on Body Weight and Obesity..………………...39 
1.3.8   Ghrelin in Pancreatic Islet Cells and its Association with Islet Cells 
Hormones……………………………......…………………………….....40 
1.3.8.1   Ghrelin and Insulin..……………….……................................40 
1.3.8.2   Ghrelin and Other Islets Hormones..……................................41 
1.3.9   Ghrelin Effect on Diabetes Mellitus....…………………………...42 
1.3.10   Other Functions and Role of Ghrelin in Different Tissues……...42 
1.4   Streptozotocin and its Diabetogenic Effects.…...…………………….45 
Chapter 2: Hypothesis, Aims and Objectives……………………………………...47 
Chapter 3: Materials and Methods…………………………………………………48 
3.1   Animal Models.…...………………………………………………….48 
3.2   Induction of Experimental Diabetes Using Streptozotocin.………….48 






3.4   Fasting Blood Glucose and Body Weight Measurements...………….50 
3.5   Glucose Tolerance Test...…………………………………………….50 
3.6   Blood and Tissue Collection ...……………………………………….51 
3.7   Tissue Processing …...……………………………………………….51 
3.7.1   Tissue Processing for Immunohistochemistry and 
Immunofluorescence Study………………....…………………………...51 
3.7.2   Tissue Processing for Electron Microscopy……………………...52 
3.8   Immunohistochemistry Study: Avidin-Biotin Complex Staining 
Method for Paraffin Section....…………………………………………….53 
3.9   Double Labeling Immunofluorescence Staining Method for Paraffin 
Sections…………………………....……………………………………….54 
3.10   Transmission Electron Microscopy Post-embedding Immunogold 
Double Labeling Protocol…....…………………………………………….55 
3.11   Enzyme-Linked Immunosorbent Assay…………………………….56 
3.12   Biochemical Analysis……………………………………………….58 
3.13   Statistical Analysis………………………………………………….58 
Chapter 4: Results …………………………………………………………………59 
4.1   Effect of Ghrelin Treatment on Fasting Blood Glucose Level of 
Normal and Diabetic Wistar Rats………………………………………….59 
4.2   Effect of Ghrelin Treatment on Body Weight of Normal and Diabetic 
Wistar Rats……………..………………………………………………….60 
4.3   The Effect of Four Weeks of Ghrelin Treatment on Preventing or 
Delaying the Onset of STZ-induced Diabetes Mellitus in Wistar 
Rats……………………..………………………………………………….61 
4.4   The Effect of Ghrelin Treatment on Glucose Tolerance Test.……….62 
4.5   Summary and Discussion – I…...…………………………………….63 
4.6   Immunohistochemical Localization of Insulin and Ghrelin in Normal 
and Diabetic Rat Pancreas.…..…………………………………………….64 
4.6.1   Insulin……………..………………....…………………………...64 






4.7   Summary and Discussion – II…..…………………………………….69 
4.8   Effect of Ghrelin on Serum Insulin Level...………………………….70 
4.9   Summary and Discussion – III ...…………………………………….71 
4.9.1  Co-Localization of Ghrelin with Insulin and Glucagon in Pancreatic 
Islet Cells…………………………………....…………………………...72 
4.9.1.1   Ghrelin and Insulin..……………….……................................72 
4.9.1.2   Ghrelin and Glucagon..…………….……................................74 
4.9.2   Localization of Ghrelin and Insulin in the Secretory Granules of 
Pancreatic β Cells………...………………....…………………………...76 
4.9.2.1   Wistar Normal Control Rat..……….……................................76 
4.9.2.2   Wistar Normal Treated Rat..……….……................................77 
4.9.2.3   Wistar Diabetic Control Rat……….……................................78 
4.9.2.4   Wistar Diabetic Treated Rat……….……................................79 
4.10   Summary and Discussion – IV..…………………………………….80 
4.11   Effect of Ghrelin Treatment on Liver Function…………………….81 
4.11.1   Alanine Transaminase…...………....…………………………...81 
4.11.2   Aspartate Transaminase….………....…………………………...82 
4.12   Summary and Discussion – VII….………………………………….83 
Chapter 5: Summary ………………………………………………………………84 
Chapter 6: Discussion ..……………………………………………………………85 
Chapter 7: Conclusion..……………………………………………………………88 
Chapter 8: Limitations and Future Prospective……………………………………89 
Bibliography...……………..………………………………………………………90 







List of Tables 
 
Table 1: The prevalence of diabetes mellitus in the Middle East and North Africa. . 14 
Table 2: Classification of different type of insulin injection according to their 
duration of action. ...................................................................................................... 25 
Table 3: List of names and dilutions of the primary and secondary antibodies used in 








List of Figures 
 
Figure 1: Location of the pancreas. .............................................................................. 2 
Figure 2: Structure of the pancreas. ............................................................................. 2 
Figure 3: Pancreatic blood supply and innervations. ................................................... 3 
Figure 4: Distribution of pancreatic endocrine cells. ................................................... 5 
Figure 5: Discoverer of insulin. ................................................................................... 7 
Figure 6: Structure and formation of insulin. ............................................................... 8 
Figure 7: Insulin receptor. .......................................................................................... 10 
Figure 8: Mechanism of action of Insulin. ................................................................. 11 
Figure 9: Diabetes mellitus symptoms. ...................................................................... 19 
Figure 10: Diabetes mellitus complications. .............................................................. 21 
Figure 11: Sulfonylureas mechanism of action. ......................................................... 26 
Figure 12: Schematic illustration of the mechanism of action of metformin on the 
liver cell. ..................................................................................................................... 27 
Figure 13: Ghrelin synthesis and structure................................................................. 35 
Figure 14: Signaling pathway of ghrelin-inducing GH release. ................................ 37 
Figure 15: Signaling pathway of ghrelin-inducing food intake in the hypothalamus.38 
Figure 16: Ghrelin signaling in islet β cells. .............................................................. 41 
Figure 17: Physiological action of ghrelin. ................................................................ 44 
Figure 18: Streptozotocin mechanism in inducing diabetes mellitus......................... 46 
Figure 19: Schematic drawing describing animal groups in this study. .................... 49 
Figure 20: Schematic drawing explaining the study design of pre-diabetic ghrelin-
treated group............................................................................................................... 50 
Figure 21: Illustration of Mercodia Ultrasensitive Rat Insulin ELISA protocol. ...... 57 
Figure 22: Effect of ghrelin treatment on fasting blood glucose level of normal and 
diabetic wistar rats...................................................................................................... 59 
Figure 23: Effect of ghrelin treatment on body weight of normal and diabetic wistar 
rats. ............................................................................................................................. 60 
Figure 24: The effect of four weeks of ghrelin treatment on preventing or delaying 
the onset of STZ-induced diabetes mellitus in wistar rats. ........................................ 61 
Figure 25: The effect of ghrelin treatment on glucose tolerance test. ........................ 62 
Figure 26: Immunohistochemical localization of insulin and ghrelin in normal and 
diabetic rat pancreas. .................................................................................................. 66 
Figure 27: Percentage of insulin- and ghrelin-immunopositive cells. ....................... 68 
Figure 28: Effect of ghrelin on serum insulin level. .................................................. 70 
Figure 29: Co-localization of ghrelin with insulin in pancreatic islet cells. .............. 73 
Figure 30: Co-localization of ghrelin with glucagon in pancreatic islet cells............ 75 
Figure 31: Localization of ghrelin and insulin in the secretory granules of pancreatic 
β cells of normal control rats. ..................................................................................... 76 
Figure 32: Localization of ghrelin and insulin in the secretory granules of pancreatic 






Figure 33: Localization of ghrelin and insulin in the secretory granules of pancreatic 
β cells of diabetic control rats. ................................................................................... 78 
Figure 34: Localization of ghrelin and insulin in the secretory granules of pancreatic 
β cells of diabetic ghrelin-treated rats. ....................................................................... 79 
Figure 35: Serum Alanine Transaminase levels......................................................... 81 
Figure 36: Serum Aspartate Transaminase levels. ..................................................... 82 
Figure 37: Summary of the outcomes in this study. .................................................. 84 






Chapter 1: Introduction 
 
1.1 Pancreas 
The word pancreas is derived from Greek word “Pan-Kreas” that means all 
flesh. The pancreas is an elongated, soft, J shaped gland. It is light pink in color, 
measures approximately 12-15 cm in length  and weighs about 70 – 100 g (Tan, 
2008). It was the last organ in the abdomen to attract the attention of anatomists, 
physiologists, physicians and surgeons. 
It is located in the abdominal cavity, in the upper part, behind the stomach 
(Figure 1). The Pancreas is divided into 4 parts: head, neck, body and tail (Figure 2). 
The head, which is the wider end of the pancreas, lies within the curvature of the 
duodenum. The rest of the pancreas lies obliquely in the posterior abdomen, with the 
tail extending as far as the gastric surface of the spleen. The neck connects the head 
to the main part of the pancreas: the body. The latter is the biggest and main part of 
the pancreas located to the left of the superior mesenteric blood vessels. The 
superior mesenteric vein joins the splenic vein behind the neck of the pancreas to 
form the portal vein (Moore & Dalley, 1999). The pancreas receives it’s blood 
supply from the superior and inferior pancreaticoduodenal arteries, while the splenic 
artery supplies the tail and part of the body of the pancreas (Figure 3) (Faiz & 
Moffat, 2006). 
The pancreas is divided into lobules by connective tissue septae (Guyton, 
1981). This organ plays a dual role as a secretory gland (Eroschenko, 2008), with 
both exocrine and endocrine functions. The exocrine part makes, secretes and 
releases digestive enzymes into the duodenum. While, the endocrine part, which is 






variety of pancreatic hormones into the blood stream (Petersen, 1992).  
 
Figure 1: Location of the pancreas. 
“Reproduced and edited (Faiz & Moffat, 2006)”. 
 
 
Figure 2: Structure of the pancreas. 








Figure 3: Pancreatic blood supply and innervations. 
“Reproduced and edited (Faiz & Moffat, 2006)”. 
 
1.1.1 Exocrine Part of the Pancreas 
The exocrine part is a grape-like cluster of acinar cells which comprises 
more than 95% of the pancreas mass. This portion of the pancreas is responsible for 
making and secreting the digestive enzymes which are released into the duodenum. 
It is composed mainly of acinar and ductal cells with associated connective tissue, 
vessels and nerves. The main pancreatic duct is referred to as “Wirsung”, which 
begins from the tail and runs to the head of the pancreas to join the common bile 
duct to form the hepatopancreatic ampulla (Bockman, Büchler, & Beger, 1986).  
The accessory pancreatic duct, which is referred to as the duct of “Santorini” is 
superior to the opening of the main duct. The two ducts are responsible for draining 
the exocrine secretions through the ampulla of Vater into the duodenum (Campbell 
& Verbeke, 2013; Eroschenko, 2008). Digestive enzymes, bicarbonate, NaCl and 
water are secreted into the duodenum via pancreatic ducts. These enzymes help in 






the duodenum (Ganong, 2005; Pandol, 2011). 
1.1.2 Endocrine Part of the Pancreas 
Endocrine cells, limited to about 1-2% of the whole pancreatic tissue, 
(Barrett, Ghishan, Merchant, Said, & Wood, 2006; Greenstein & Wood, 2011; 
Tortora & Derrickson, 2011), regulate pancreatic and gastrointestinal functions and 
regulate energy metabolism of the whole-body. The endocrine part is composed 
mainly of four types of cells: Alpha (α) (17%), Beta (β) (70%), Delta (δ)(7%) and 
PP or Gamma (γ) (Figure 4).  
These cells together form what is called the islet of Langerhans, first 
described by the German doctor, Paul Langerhans in 1869 (Karamitsos, 2011; 
Rosenfeld, 2002a). These cells are richly vascularized and embedded within the 
exocrine tissue (Ganong, 2005). Recently, a new cell type termed epsilon (Є) cells 
has been discovered in the islets of Langerhans (Ross & Pawlina, 2006). Pancreatic 
islet cytoarchitecture differs between species. In rodents, β cells are predominantly 
found as a cluster in the core of the islet, while α, δ and γ cells are scattered in the 
periphery. On the other hand, human β cells are not clustered and the majority of the 
β cells are shown to be scattered in the islet in association with α and δ cells 







Figure 4: Distribution of pancreatic endocrine cells. 
“Modified from Trends Endocrinology and  Metabolism, 2012” (Efrat & Russ, 
2012). 
1.1.3 Hormones of the Pancreas 
The endocrine part of the pancreas produces important hormones such as 
insulin, glucagon, somatostatin and pancreatic polypeptide, which play a key 
regulatory role in several metabolic functions either systemically, regionally (in the 
gastrointestinal tract) or locally (in the islet) (Ross & Pawlina, 2006). 
1.1.3.1 Insulin 
Insulin is a polypeptide hormone composed of 51 amino acids distributed in 
2 polypeptide chains, which are linked together by two disulfide bridges [(Figure 
5.A); (Harvey & Ferrier, 2011)]. Insulin is the most abundant endocrine polypeptide 
(Ross & Pawlina, 2006) and the most well-known pancreatic hormone produced by 
β cells (Tan, 2008). Insulin secretion is stimulated by elevated blood glucose level 







1.1.3.1.1 Discovery of Insulin 
In 1920, Frederick Banting had the idea that pancreatic digestive enzymes 
are harmful to the secretions produced by pancreatic islet of Langerhans. In 1921, 
Banting took his theory to Professor John Macleod at the University of Toronto. 
Macleod who was a leading figure in diabetes research in Canada provided Banting 
with a laboratory, a minimum number of equipment and ten dogs. Charles Best, a 
medical student joined Banting to assist him in the experiments which was assigned 
to start in the summer of 1921. They removed the pancreas from one dog and 
observed that the dog became very weak, thirsty and urinated more often. The dog 
blood glucose rose and it had developed diabetes. Using another dog, both Banting 
and Best surgically ligated the pancreas to prevent the flow of nourishment which 
will result in degeneration of the pancreas. Later on, they isolated the pancreas, froze 
it, grinded it and filtered it. When the diabetic dog (first dog) was injected with the 
filtered extract, its blood glucose dropped. Its health appeared to be improving and it 
was symptoms free with the repetitive administration of the extract, which Banting 
and Best called “isletin”. In late 1921, the biochemist, Bertram Collip joined 
Banting and Best, and his task was to help in purifying the pancreatic extract so it 
can be tested in human. In April, 1922 when Canadian researchers decided on the 
name of insulin, which had been proposed by a Belgian doctor a few years prior to 
its isolation. Collip succeeded in purifying the extract and it was not until January 
1923 when he witnessed the first administration of “insulin” by intramuscular 
injected to Leonard Thomson, a 14-year-old boy, who weighed a mere 27 kg. It was 
a dramatic moment to see his blood glucose level drop from 440 to 320 mg/dl. The 
observation of Leonard’s health after the insulin injection encouraged the team to 






response as Leonard to the insulin extract. The Nobel Prize was awarded to Banting 
and Macleod on October 26th, 1923. Banting shared his half with Best, while 
Macleod split his with Collip (Karamitsos, 2011; Pavel & Sdrobici, 1972; “The 
Discovery of Insulin,” n.d.) (Figure 5). 
 
Figure 5: Discoverer of insulin. 
From top, J.J.R. Macleod (left), Frederick Banting (right), from bottom, Charles 






1.1.3.1.2 Synthesis of Insulin 
As shown in Figure 6.B, insulin is the end product of an inactive precursor 
called preproinsulin. First, “proinsulin” is generated after cleavage of its N-terminal 
signal peptide during insertion into the endoplasmic reticulum (ER). Proinsulin 
consists of three domains: an N-terminal B chain, a connecting peptide in the middle 
known as the C peptide and a C-terminal A chain.  Within the ER, proinsulin is 
exposed to several specific endopeptidases, which excise the C peptide and so yield 
the mature insulin. Finally, the mature form of insulin and the free C-peptide are 
packaged in the Golgi apparatus to form secretory granules which accumulate in the 
cytoplasm. Since C-peptide and insulin are produced at the same rate, C-peptide is a 
useful marker that indicates the effectiveness of insulin production and secretion in 
early DM (Harvey & Ferrier, 2011). 
 
Figure 6: Structure and formation of insulin. 








1.1.3.1.3 Function of Insulin 
The principal actions of insulin take place in the liver, skeletal muscle and 
adipose tissue (Ross & Pawlina, 2006). Insulin lowers the glucose level in the blood 
by accelerating the membrane transport of glucose into the liver, muscles cells and 
adipose cells. Insulin accelerates the conversion of glucose into glycogen in liver 
cells (Eroschenko, 2008). Insulin does not only influence glucose metabolism, but 
also plays a role in protein and fat metabolism  (Tan, 2008). 
1.1.3.1.4 Receptors of Insulin 
The insulin receptor, which belongs to the tyrosine kinase superfamily, is a 
heterotetrameric glycoprotein that comprises two subunits: α (723 amino acids) and 
β (620 amino acids). Alpha subunits exist primarily extracellularly, while β subunits 
are transmembrane proteins. Both subunits are connected together with disulfide 
bonds (Fig. 7). Binding of insulin molecules to α subunits lead to conformational 
changes of the receptors resulting in an autophosphorylation of tyrosine residues by 
enabling ATP to bind to the β subunits in the intracellular domain (De Meyts, 2004; 
Hubbard, 2013; C. R. Kahn & White, 1988; Kido, Nakae, & Accili, 2001). 
Insulin receptors are expressed on virtually all mammalian tissues. The 
number of receptors varies from one site to another with nearly more than 200,000 
receptors on adipocytes and hepatocytes. The brain was initially thought to be an 
insulin-dependent organ. This was based on the awareness that insulin cannot 
permeate the blood-brain barrier (C. R. Kahn & White, 1988; Watanabe, Hayasaki, 
Tamayama, & Shimada, 1998), but the brain has been shown to have insulin 







Figure 7: Insulin receptor. 
“Reproduced and edited (Harvey & Ferrier, 2011)”. 
 
1.1.3.1.5 Mechanism of Action of Insulin 
Once insulin binds to the α-subunits of the receptor, it provokes many 
reactions like the rapid recruitment of insulin-sensitive glucose transporters (GLUT-
4) into adipocytes and skeletal muscle cells from a pool located in intracellular 
vesicles. After the autophosphorylation of β subunits, which in turn phosphorylate 
many other proteins such as the insulin receptor substrate proteins (IRS’s). IRS’s, 
then activate multiple signaling pathways and lead to many biological effects known 
to be exerted by insulin like facilitating the availability of glucose receptors and 








Figure 8: Mechanism of action of Insulin. 
“Reproduced and edited (Harvey & Ferrier, 2011)”. 
 
1.1.3.2 Glucagon 
Glucagon is the second most important pancreatic endocrine hormone after 
insulin and it is secreted by α cells. Glucagon is usually released in response to low 
levels of glucose in the blood (Eroschenko, 2008). Its actions are essentially 
reciprocal to those of insulin. For example, it stimulates the release of glucose into 
bloodstream, glyconeogensesis and glyconeolysis in liver as well as the proteolysis 
to promote gluconeogenesis, mobilizes fats from adipose tissue cells and stimulates 
hepatic lipase (Ross & Pawlina, 2006). 
1.1.3.3 Somatostatin 
Somatostatin, which is produced by δ dells, acts in a paracrine manner to 
inhibit insulin and glucagon secretion. Moreover, it plays a role in slowing the 
absorption of nutrients from the gastrointestinal tract, gallbladder and inhibiting GH 






1.1.3.4 Pancreatic Polypeptide 
PP cells also known as γ cells secrete a pancreatic polypeptide hormone, 
which inhibits somatostatin secretion, gallbladder contraction and secretion of 
digestive enzymes by the pancreas (Tortora & Derrickson, 2011). PP has been 
implicated in the regulation of energy balance (Asakawa et al., 2003). 
1.1.4 Diseases of the Pancreas 
Many diseases and disorders have been reported to affect the pancreas. In 
addition to developmental anomalies, and trauma, two distinct types of acute and 
chronic pancreatitis are the most common conditions along with pancreatic cancer. 
The pathogenesis of these disorders is not well established, yet all of them share the 
genetic, immunologic and environmental involvement in the manifestation of each 
and every one of them. Unfortunately, no cure is available till today. Patient  therapy 
revolves around pain management and delaying the progression by medication, diet, 
endoscopy and surgery (Baker, 2004; Braganza, Lee, McCloy, & McMahon, 2011; 
DiMagno & DiMagno, 2012, 2012; Frossard, Steer, & Pastor, 2008, p. -; D. Li, Xie, 
Wolff, & Abbruzzese, 2004; Mitchell, Byrne, & Baillie, 2003; Spalding & 
Williamson, 2011; Vincent, Herman, Schulick, Hruban, & Goggins, 2011). 
 Diabetes Mellitus (DM) is one of the major disorders affecting the pancreas. 











1.2 Diabetes Mellitus 
1.2.1 History of Diabetes Mellitus 
The burden of DM has been growing over the years. DM which is becoming 
an epidemic disease is not a new phenomenon. DM is thought to have been 
described for the first time by an Egyptian called Hesy-Ra, who described a rare 
disease which causes loss of body weight, along with a frequent urge to urinate circa 
1552 BC. 
Aretaeus (30-90CE), the Greek physician was the one who gave diabetes its 
name (which in Greek means "flowing through"), when he recorded the symptoms 
of constant thirst, frequent urination and loss of body weight. Aretaeus thought it 
was a disease of the kidneys. In his book “Causes and Indications of Acute and 
Chronic Diseases”, Aretaeus distinguished between DM and diabetes insipidus 
(Ahmed, 2002). 
In 1025, in the book, “Canon of Medicine”, Avicenna, also known as Ibn 
Sina (The famous Arabian Physician) described the symptoms and the complications 
of DM in detail. 
The term “diabetes” came from the Greek word “diabinein”, which means 
“to pass through”, and later, in 1675 the Latin word “mellitus”: i.e. honey-sweet’ 
was added by the British physician and neuroanatomist, Thomas Willis (Howarth, 
2013). 
At that same time, an Indian physician called “Charaka Samhita”, identified 
diabetes and called it “madhumeha”, which means “honey urine”, when he  noticed 
that the urine attracts ants and he started to use ants to diagnose his patients with 






identify the difference between the two main types of DM, noticing that thin patients 
developed diabetes at  a younger age compared to obese patients (“dLife Diabetes 
Museum,” n.d.). 
1.2.2 Epidemiology and Prevalence of Diabetes Mellitus 
As the human population’s growth, obesity, sedentary lifestyle, urbanization 
and aging increases, the prevalence of DM also increases (Wild, Roglic, Green, 
Sicree, & King, 2004). The fast increase of diabetes prevalence and the severity of 
its complications are complex challenges that researchers face. A lot of effort is 
invested in understanding the complexity of DM and many studies are searching for 
ways to cure DM, prevent it or delay its progression.  
The sixth edition of the Diabetes Atlas published by the International 
Diabetes Federation estimated that, in 2014, 36.8 million people were diagnosed 
with DM in the Middle East and North Africa regions (“Diabetes Atlas | 
International Diabetes Federation,” n.d.), which corresponds to 9.7% of the 
population (Table 1). 
 
Table 1: The prevalence of diabetes mellitus in the Middle East and North Africa. 
Modified from International Diabetes Federation, Diabetes Atlas, 6th edition, 2014 







Epidemiologists have looked into the prevalence of DM from many aspects, 
including the role that geographical location, ethnicity and gender play. Some 
reports indicate a higher prevalence of type 1 diabetes mellitus (T1DM) in men, 
while type 2 diabetes mellitus (T2DM) was reported to be higher in women. 
However, in another study which was conducted in a Mexican population, T2DM 
was found to be higher in men than in women. In addition, T1DM was found to be 
highest in Scandinavian and lowest in Japanese population (Ernest Adeghate, 
Schattner, & Dunn, 2006a). 
An unhealthy diet and lack of exercise played a role in listing some of the six 
Gulf Cooperation Council Countries among the world’s top 10 countries with the 
highest prevalence of DM (Guariguata et al., 2014). DM prevalence is estimated to 
be 9% and 25% in Bahrain, 16.1% in Oman, 21.4% in Kuwait, 16.7% in Qatar, 
23.7% in Saudi Arabia and  23.3% in the United Arab Emirates(Howarth, 2013). 
1.2.3 Definition of Diabetes Mellitus 
According to the World Health Organization (WHO) report in 1999, DM is a 
metabolic disorder of multiple etiologies, characterized by chronic hyperglycemia 
with disturbance in carbohydrate, fat and protein metabolism, which results from 
defects in insulin secretion, action or both (“Diagnosis and Classification of 
Diabetes Mellitus,” 2010, “WHO | Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycaemia,” n.d.). 
1.2.4 Classifications of Diabetes Mellitus  
DM was previously classified on the basis of insulin dependent treatment, 






physiological and morphological changes. In literature, T1DM and T2DM are 
known to be the main types of DM. Gestational diabetes (GDM) is another common 
type of DM which is less prevalent than the other two. Less common classes of DM 
include Maturity Onset Diabetes of the Young (MODY), pancreatic DM and others 
(See sections 1.2.4.3 & 1.2.4.4). 
1.2.4.1 Type 1 Diabetes Mellitus 
T1DM was previously called “Insulin Dependent Diabetes Mellitus 
(IDDM)” or “juvenile diabetes”; because it occurs in childhood or is young adults.  
About 5-10% of cases of DM are T1DM, where the pancreas is either unable 
to produce insulin or it does but in very small amounts that do not meet the body’s 
need to maintain its function. This may be a consequence of selective pancreatic β 
cells autoimmune destruction leading to a crucial decrease in the mass of these cells 
in the islets of Langerhans (E. Adeghate, 2001). 
The events that trigger the autoimmune response remain unclear. The 
pathogenesis of T1DM is known to involve recruitment of CD4+ helper and CD8+ 
killer T lymphocytes and infiltration of macrophages causing certain interleukins to 
attack and destroy pancreatic islets (Gillespie, 2006). 
Antibodies against insulin secreting cells, including those against insulin, 
glutamic acid decarboxylase and against the whole islet cells are known to be 
involved in the development of T1DM pathogenesis (45) and can be detected at 
birth or in infancy (Skyler & Sosenko, 2013). 
Some researchers suspect a connection between some viruses and T1DM, 
especially when alpha interferon was found to be expressed in patients at the onset 






20 – 30% of patients with T1DM. Likewise, an increase in congenital rubella and 
mumps incidences (Ernest Adeghate, Schattner, & Dunn, 2006b), as well as 
enterovirus and rotavirus infections (Gillespie, 2006) were consistent with increased 
cases of T1DM. 
Moreover, patients with T1DM were found to have other autoimmune 
disorders such as Addison’s and autoimmune thyroid (Ernest Adeghate et al., 
2006b).  
1.2.4.2 Type 2 Diabetes Mellitus 
The majority of patients (around 90%) diagnosed with DM have T2DM 
which previously was called “Non-Insulin Dependent Diabetes Mellitus (NIDDM)”.  
T2DM is characterized mainly by insulin resistance with association of 
relatively reduced insulin secretion (S. E. Kahn, 2000; Stumvoll, Goldstein, & van 
Haeften, 2005). T2DM predisposition relies on lifestyle and genetics factors(Leahy, 
2005). Obesity for instance is the main lifestyle factor which contributes in the 
manifestation and development of T2DM (S. E. Kahn, Hull, & Utzschneider, 2006; 
Mokdad AH, Ford ES, Bowman BA, & et al, 2003). Other factors known to increase 
the risk of developing T2DM are persistent stress and drugs like corticosteroids and 
oral contraceptives (Ernest Adeghate et al., 2006b). 
1.2.4.3 Gestational Diabetes Mellitus 
GDM is another common form of DM known to occur in late gestation and 
is characterized by insulin resistance (Ernest Adeghate et al., 2006b). A study done 
on Iranian women showed an increased risk of developing GDM in women with 
polycystic ovarian syndrome (Ashrafi et al., 2014). Women who develop GDM are 






1.2.4.4 Other Types of Diabetes Mellitus  
Many cases do not fit into the above classification, yet these cases are 
considered to be DM. A specific type of DM may be caused by a mutation in the 
insulin receptor and or by genetic impairment of pancreatic β cells, whereas some 
may be caused by insufficient insulin release and impaired action. Other cases of 
DM may be a consequence of toxin-induced DM. Alzheimer’s disease, caused by 
abnormal amyloid protein has been  considered by some as the third type of DM 
(T3DM) (American Diabetes Association, 2014; Pilcher, 2006). 
MODY is another form of DM which is inherited in autosomal dominant 
trait. The hyperglycemia appears after puberty and is detectable before the age of 
twenty-five years. MODY is treatable without insulin involvement for the first five 
years of the onset, yet later on it will require insulin injection like T1DM. MODY 
prevalence varies from one population to another. For example it was found that 
Blacks and Indian populations have about 10% prevalence, while Caucasians were 
found to have less than 1%.  
1.2.5 Symptoms of Diabetes Mellitus 
Diabetic patients may or may not present characteristic symptoms of 
polyuria, continued thirst ‘polydipsia’(Ernest Adeghate et al., 2006b), dramatic loss 
of body weight and blurred vision. Without adequate management and treatment 
patients will develop a severe form of ketoacidosis or non-ketotic hyperosmolar 
state, which will become a life threating condition when it develops to stupor, coma 







Figure 9: Diabetes mellitus symptoms. 









1.2.6 Criteria for Diagnosis of Diabetes Mellitus 
According to the American Diabetes Association (ADA), to diagnose DM 
one of the following three measurements should be positive: 
1 A fasting plasma glucose (FPG) level ≥126 mg/dL (7.0 mmol/L), or 
2 A 2-hour plasma glucose level ≥200 mg/dL (11.1 mmol/L) during a 
75 g oral glucose tolerance test (OGTT), or  
3 A random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in a patient 
with classic symptoms of hyperglycemia and or hyperglycemic 
crises 
1.2.7 Complications of Diabetes Mellitus 
In DM chronic hyperglycemia eventually will cause damage, dysfunction 
and failure of various organs like the eyes, kidneys, nerves, heart and blood vessels 
(Figure 10). Life-threatening and disabling complications have been also reported, 
especially if DM is poorly controlled (“Diagnosis and Classification of Diabetes 
Mellitus,” 2010, “WHO | Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycaemia,” n.d.). 
Complications differ from patient to patient and vary in severity. 
Retinopathy, nephropathy, peripheral neuropathy, autonomic neuropathy and sexual 
dysfunction are all found among patients with DM. Also incidences of cardiac 
complications have been reported to increase in patients with DM. These 








Figure 10: Diabetes mellitus complications. 






A study conducted in Al Ain City, in the United Arab Emirates showed that 
the prevalence rates of retinopathy, neuropathy, nephropathy, peripheral vascular 
diseases and congestive heart disease were 54.2%, 34.7%, 40.8%, 11.1% and 10.5%, 
respectively (Saadi et al., 2007). 
Blindness and end-stage renal damage are highly prevalent among patients 
with DM. Also poorly controlled DM patients are more susceptible to bacterial and 
fungal infections, and developing diabetic foot ulcers (E. Adeghate, 2001). 
1.2.8 Management and Treatment of Diabetes Mellitus 
There are four main aims of DM treatment. First is to enhance the glycemic 
control, second is to slow the progression of the disease, third is to prevent 
complications and fourth is to improve quality of life (Shrivastava, Shrivastava, & 
Ramasamy, 2013). The aims can be achieved with body weight reduction and active 
lifestyle which are considered to be important factors in treating patients with 
T2DM, whereas the main corner stone is patient’s compliance to the medications 
regimen (Bonora, 2008). 
1.2.8.1 Nutrition 
A healthy and balanced diet helps in controlling blood sugar level in diabetic 
patients. There is no ideal percentage of caloric intakes, typical food plan or eating 
pattern that works universally. However individualized nutrition therapy depending 
on patient preferences and metabolic goals should be taken into consideration. A 
registered dietitian should be assigned to follow up with each and every diabetic 







A gradual and sustained body weight reduction is important for obese 
patients with DM or at risk of developing it. It has been shown that body weight 
reduction is effective not only in preventing the onset of the disease and its 
progression, but also it helps in ameliorating the acute and long-term DM 
complications (“REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES 
WITH LIFESTYLE INTERVENTION OR METFORMIN,” 2002). 
1.2.8.2 Exercise 
Many researches in the literature reported that exercise can be a cornerstone 
in the management of DM. Lack of exercise among other lifestyle habits like 
smoking and alcohol consumption was proven to increase the risk of developing 
T2DM (Hu et al., 2001). However, Different types of exercise are effective in DM 
management, and physicians should tailor individualized programs for each DM 
case depending on the glycemic reading especially for those with T1DM; to meet 
their therapeutic goals (Colberg & Swain, 2000). 
The role of exercise is not as clear in T1DM as it is in T2DM, and fear of 
hypoglycemia and worsening of the complications in T1DM should be taken into 
consideration when introducing exercise or any other regular physical activity as one 
of the management approaches (Horton, 1988). Increasing insulin sensitivity, 
lowering blood glucose level, enhancing lipid profile, reducing the risk for 
hypertension and positively affecting the psychological status are well-known 
effects of exercise on T2DM, whereas with T1DM the fluctuation between hypo- 
and hyperglycemia can be managed by careful monitoring of blood glucose level, 
adjusting insulin doses and following appropriate diet (Riddell & Perkins, 2006; 







In T2DM; Diet, body weight reduction and exercise may not be sufficient to 
meet the glycemic control and oral glucose-lowering agents will be introduced to the 
patients. T2DM patients might require insulin injection to approach their glycemic 
goal; whereas, patients with T1DM depend mainly on insulin for survival. 
1.2.8.3.1 Insulin Treatment of Diabetes Mellitus 
Insulin is not administered orally because as a peptide hormone it will 
rapidly be broken down or digested by the acids in the stomach or by proteolytic 
enzyme, respectively; hence insulin is not administered orally. The most common 
route of administration for insulin is subcutaneous. Many forms of insulin are 
available and it is common practice to use combination therapy of at least two forms 
of insulin to treat patients with T1DM. 
Insulin forms differ in their origin, onset and duration of action. Aspart, 
Lispro and Glulisin are known to be rapid acting insulin with fast onset (15 - 30 
minutes), while regular insulin is a short acting type of insulin. Isophane insulin, 
insulin zinc suspension and protamine zinc insulin are intermediate acting types of 
insulin with onset of action of approximately 1 – 2 hours, while glargine and detemir 
are long acting analogues of human insulin (Committee, 2014) (Table 2).  
Another form of insulin is Exubera which was approved by the Food and 
Drug Administration (FDA) was the first inhaled form of insulin(Wells et al., 2008). 
This drug has now been withdrawn because of concerns of developing lung cancer 
(Heinemann, 2010) but a new inhalable insulin called Afrezza was approved by the 







Table 2: Classification of different type of insulin injection according to their 
duration of action. 
“Reproduced and edited (DiPiro et al., 2011)” 
 
1.2.8.3.2 Oral Antidiabetic Agents 
The FDA has approved six classes of antidiabetic agents to treat T2DM; each 
class of antidiabetic agent has a different mechanism of action.  




3. Thiazolidinediones (TZD’S) or glitazones  
4. Alpha glucosidase inhibitors 
5. Other antidiabetic agents  
1. Incretin mimetics 
2. Dipeptidyl peptidase – IV inhibitors (DPP4) 






1.2.8.3.2.1 Insulin Secretagogues 
Sulfonylureas and meglitinide analogs act by enhancing the release of 
insulin. Sulfonylureas differ in potency (second generation agents are more potent), 
potential side effects and plasma protein binding affinity. As shown in Figure 11, 
sulfonylureas act predominantly through blocking of the ATP-sensitive K
+
 channel 
leading to depolarization of the β cell membrane and Ca
2+ 
influx, resulting in 
exocytosis of insulin granules. 
Meglitinide analogs like repaglinide, a benzoic acid derivative and 
nateglinide, aphenylalanine amino acid derivative are both considered to be short 
acting insulin secretagogues. Both necessitate the availability of glucose to exert 
their effect, which is similar to sulfonylureas.  
 
Figure 11: Sulfonylureas mechanism of action. 








Metformin is the only agent available in this class and achieves its action not 
by directly acting on β cells but rather by augmenting insulin sensitivity of both 
hepatic and peripheral (muscle) tissues leading to increased uptake of glucose 
(Figure 12).  
 
 
Figure 12: Schematic illustration of the mechanism of action of metformin on the 
liver cell. 
“Reproduced and edited (Rena, Pearson, & Sakamoto, 2013)” 
It was shown that pre-gestational use of metformin reduces the risk of 
developing GDM (Ashrafi et al., 2014). Metformin has also been used to treat 
polycystic ovarian syndrome, which can contribute to GDM (Reyes-Muñoz et al., 
2012; Weerakiet et al., 2004).  
1.2.8.3.2.3 Thiazolidinediones or Glitazones 
Thiazolidinediones (TZD’s) or glitazones were introduced as a treatment of 
T2DM in 1996, when troglitazone was approved by the FDA. Unfortunately 






hepatoxicity) in 2000(Kendall, 2006). Other agents such as pioglitazone and 
rosiglitazone were approved as treatment for T2DM. Glitazones act by inhibiting 
peroxisome proliferator activator receptor γ (PPAR γ) which is located in vascular 
and fat cells. This class of drugs enhances insulin sensitivity in muscle, liver as well 
as fat tissues and results in increased the level of high density lipoproteins (HDL) 
with a slight reduction in blood glucose level. It is a regular clinical procedure to 
initially perform a liver function test before start the treatment with any of the 
glitazones and to repeat it periodically thereafter. 
1.2.8.3.2.4 α-Glucosidase Inhibitors 
Acarbose and miglitol, reversibly bind to and inhibit α-glucosidase in the 
membrane of the intestinal brush border. Both are taken at the beginning of meals to 
exert their effects by delaying the digestion of carbohydrates resulting in lower 
postprandial glucose level. They also inhibit pancreatic amylase and interfere with 
the breakdown of starch. Since α-glucosidase inhibitors have no effect whatsoever 
on insulin secretion and insulin function, it will not result in hypoglycemia if it is 
used as a monotherapy. Side effects of this drug may include flatulence, abdominal 
cramps and diarrhea, along with complete inhibition of some enzymes such as, 
maltase, iso-maltase and glucoamylase which will interfere with absorption of these 
nutrients. 
1.2.8.3.2.5 Other Antidiabetic Agents 
Another two classes of hypoglyceimic agents are the incretin mimetics 
(Exenatide) and Dipeptidyl Peptidase–IV Inhibitors (DPP4; Vildagliptin and 
Sitagliptin). Both classes improve glucose dependent insulin secretion, they also 






secretion and promote β cell proliferation. Exenatide, a 39 amino acid polypeptide, 
is 50% homologous to GLP-1, yet unlike GLP-1, increases gastric secretion (Lotfy, 
Singh, Kalász, Tekes, & Adeghate, 2011)). 
Synthetic Amylin Analog (Pramlintide) is used in the treatment of both 
T1DM and T2DM patients (Ernest Adeghate & Kalász, 2011) . Pramlintide exerts 
effects similar to those of incretin mimetic agents with the additional favorable 
effect of improving satiety (Chapman et al., 2005). 
Simultaneous administration of pramlintide and insulin led to 50% reduction 
in insulin dose  and a reduced risk of hypoglycemia (Clark, Harvey, Finkel, Rey, & 
Whalen, 2011; DiPiro et al., 2011; Wells et al., 2008). 
1.2.8.4 Surgery 
Surgical intervention is usually the last resort for any disease especially if it 
is manageable or curable by other approaches. Yet, in DM a surgical approach is 
becoming more common and is usually the first choice to either eliminate risk 
factors of developing T2DM such as in obese people, or to prevent the progression 
of the disease and its complications. 
Studies revealed that 83% of patients with T2DM who have undergone 
gastric bypass maintained normal blood glucose level and HbA1c concentration 
independently from body weight loss. The astonishing remission of T2DM by 
gastric bypass is thought to be multifactorial and that gut hormones play a 
significant role, especially when a rise in postprandial GLP-1 and peptide YY 
concentrations were reported along with reduction in the basal ghrelin level 






that gastric bypass surgery has its own shortcomings including the life-long use of 
supplements (Padoin et al., 2009) 
1.2.8.4.1 Islet and Pancreatic Transplantation 
The first known attempt of islet transplantation was reported in 1893 
(McCall & Shapiro, 2014), followed by years of trials until success was met 
(Robertson, 2004). Moreover, pancreatic transplantation showed persistent success 
over the years not only in reducing mortality rates in diabetic patients but also in 
ameliorating the complications associated with it (Kelly, Lillehei, Merkel, Idezuki, 
& Goetz, 1967). 
Patients with T1DM who suffer from a history of severe hyperglycemia and 
metabolic instability may receive islet transplantation from multiple donors in 
conjunction with immunosuppressive drugs to prevent islet rejection. Islet 
transplantation has resulted in insulin independence with exceptional metabolic, 
normoglycemia (Warnock et al., 1991) and improved renal function in patients who 
received islet cells transplantation alone or in combination with kidney 
transplantation (Fiorina et al., 2003). 
Patients who are eligible for this procedure mostly have diabetes with end-
stage renal failure or frequent episodes of hypoglycemia (Gruessner & Sutherland, 
2005). 
Pancreatic organ transplantation is performed simultaneously with kidney 
transplantation with a favor of a living donor for the pancreas if possible; to 






Post-transplantation complications are common and include organ rejection, 
which is the reason behind the lifelong use of immunosuppressive therapy in 
patients with organ transplants.  
1.2.8.4.2 Other Types of Treatments 
There has always been a connection between DM and peptides especially gut 
peptides which mainly affect postprandial insulin secretion. These peptides include 
incretins such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide 1 (GLP-1) (Ahrén, 2003). Ghrelin which possess an opposite effect to 
leptin regarding hunger state (D. E. Cummings, Frayo, Marmonier, Aubert, & 
Chapelot, 2004; Higgins, Gueorguiev, & Korbonits, 2007; Hotta et al., 2009), also 
plays a role in diabetes especially in T2DM (Katsuki et al., 2004; Østergård et al., 
2003; Pöykkö et al., 2003). 
1.2.8.4.3 Glucagon-like Peptide-1 
Glucagon-Like Peptide-1 (GLP-1), is a gut-derived incretin hormone known 
to stimulate insulin and suppress glucagon. GLP-1 affects food intake and appetite 
reversibly. Using incretin enhancers and/or mimetics benefited patients with T2DM 
not only due to body weight regulation, but also by reducing fasting and 
postprandial blood glucose (Drucker & Nauck, 2006). GLP-1, aside from 
stimulating insulin secretion, inhibits glucagon release and regulates glycogen 
synthesis in adipose and muscle tissues (Drucker, 1998). 
A study where 10 patients were assigned to receive a continuous 
subcutaneous infusion of GLP-1 for a period of 6 weeks showed a reduction in 






along with an increase in insulin sensitivity and improvement in β cell function 
(Zander, Madsbad, Madsen, & Holst, 2002). 
GLP-1 also inhibits pancreatic β cell apoptosis and enhances proliferation 
and differentiation of insulin secreting β cells (Farilla et al., 2003; Perfetti, Zhou, 
Doyle, & Egan, 2000; Xu, Stoffers, Habener, & Bonner-Weir, 1999).  
1.2.8.4.4 Leptin 
Leptin or “satiety hormone”, is produced by fat cells in order to regulate fat 
storage in the body. Yet, in obese subjects it was noticed that leptin concentration is 
high and correlates to the percentage of body fats (Hickey et al., 1996), which could 
be a result of leptin-resistance, in the same manner as  insulin resistance (Considine 
et al., 1996). 
Over the years, a correlation between leptin insufficiency and DM was 
studied and reported to account leptin as one of etiological factors in the 
pathogenesis of DM, however, with the presence of a feedback regulatory system 
between insulin and leptin in regulating glucose homeostasis, leptin was  thought to 
be the best nominated therapeutic agent to replace insulin injection (B. P. 
Cummings, 2013; Kalra, 2013). 
1.2.8.4.5 Substance P 
Substance P (SP), is a neuropeptide that functions either as a neuromodulator 
or neurotransmitter (Datar, Srivastava, Coutinho, & Govil, 2004; Harrison & 
Geppetti, 2001). Some reports have shown that SP can reverse diabetes in mice 
(Tsui, Razavi, Chan, Yantha, & Dosch, 2007), yet in humans, it decreased insulin 






Furthermore, patients with T1DM were found to have low level of serum SP 
especially those suffering from diabetic neuropathy (Kunt et al., 2000). 
There is contradictory data in the literature about the effect of SP on insulin 
secretion. Some studies have reported that a low dose of SP stimulates insulin 
release and at a high dose the effect was abolished(Lundquist, Sundler, Ahrén, 
Alumets, & Håkanson, 1979), whereas others have shown the effects of SP on 
insulin release is dose-dependent (Hermansen, 1980). 
1.2.8.4.6 Ghrelin 
Ghrelin, a novel peptide was recently discovered and reported to play a role 
in insulin secretion (Ernest Adeghate & Ponery, 2004) and thought to influence DM 

















1.3.1 Discovery of Ghrelin 
“If one of our team members, Kenji Kangawa, Hiroshi Hosoda, or I, were 
not involved, ghrelin would not have been discovered.” said, Masayasu Kojima. 
After years of peptide hunting, Kangawa and his team finally succeeded in 
discovering a novel peptide named “ghrelin” from a few mg of stomach extract in 
1999 (M. Kojima et al., 1999; Masayasu Kojima, 2008; Masayasu Kojima & 
Kangawa, 2011). 
1.3.2 Structure of Ghrelin 
Ghrelin, a word derived from “ghre” which means “grow” in Proto-Indo-
European languages and “relin” which means release (Walker, Gong, Park, Zigman, 
& Sakata, 2013) to indicate its role in stimulating growth hormone release (Riley, 
Hirano, & Grau, 2002; Takaya et al., 2000). Ghrelin is a 28-amino-acid peptide 
secreted by the stomach (from that was termed X/A-like cell in rats and P/D1 cell in 
humans) (M. Kojima et al., 1999; Stengel & Taché, 2012), in which Ser3 is 
modified by n-octanoic acid which is a unique acyl modification and is essential for 
ghrelin’s activity. Ghrelin is encoded in prepro-ghrelin which on splicing yields 
three peptides; a single peptide, a mature peptide and a C-terminal peptide (Figure 
13) (Sato et al., 2012). 
In humans, at least there are four different forms of ghrelin: a non-acylated 
form, an n-octanoylated form bound to the serine-3 residue of the peptide, a 
decanoylated form, and lastly a decenoylated form (Hiroshi Hosoda, Kojima, 






the only active form and exerts different biological effects in different tissues 
(Masayasu Kojima, Hosoda, & Kangawa, 2012). However, decanoyl, hexanoyl, 
butynoyl and other lipid-modified forms of ghrelin showed some activity (Riley, 
2013; Thompson et al., 2004). 
 
Figure 13: Ghrelin synthesis and structure. 
“Reproduced and edited (Delporte, 2013)”. 
 
1.3.3 Ghrelin receptor 
Ghrelin receptor or growth hormone secretagogue receptor belongs to the G 
Protein-coupled receptor family that binds to ghrelin (Howard et al., 2001). In 
human, ghrelin receptor is encoded by a single-copy GHSR gene which is located on 
chromosome 3 (Wajnrajch, Ten, Gertner, & Leibel, 2011). GHSR gene generates 
two isoforms which differ in their carboxyl-terminal, GHS-R1a and GHS-R1b. 
GHS-R1a has seven transmembrane domains while GHS-R1b lacks the 
transmembrane domains 6 and 7. Isoform 1a is the active receptor which binds 
ghrelin and exerts signal transduction in the cell; however, the function of 1b 






GHS-R is located in both the central nervous system (CNS) as well as the 
peripheral nervous system (PNS). It was found in multi hypothalamic nuclei, 
pituitary gland (Reichenbach, Steyn, Sleeman, & Andrews, 2012), in CA2 and CA3 
regions of the hippocampus, the substantia nigra, ventral tegmental area, and dorsal 
and median raphe nuclei (Davenport et al., 2005). GHS-R is highly expressed in 
dopaminergic, cholecystokinin-containing neurons of the substantia nigra and 
ventral tegmental area of the midbrain (Zigman, Jones, Lee, Saper, & Elmquist, 
2006). 
GHS-R was also found to be expressed in the thyroid gland, pancreas, 
spleen, myocardium and adrenal gland, stomach, small and large intestines, liver, 
lung and adipose tissue, indicating the numerous roles of ghrelin  (Gnanapavan et 
al., 2002; Masayasu Kojima & Kangawa, 2005).  
1.3.4 Tissue Distribution of Ghrelin 
Ghrelin is expressed predominantly in the fundus of the stomach (Lee, 
Wang, Englander, Kojima, & Greeley, 2002), also in kidney glomerulus (Mori et al., 
2000), intestine (H. Hosoda, Kojima, Matsuo, & Kangawa, 2000), human placenta 
(Gualillo et al., 2001) and in human T cells, B cells and neutrophils (Hattori et al., 
2001). Furthermore, ghrelin was detected in human pancreas (Papotti et al., 2000) 
where many studies showed ghrelin co-localizes with insulin in β cells (Volante et 
al., 2002).Others revealed the presence of ghrelin in α cells indicating its role in 
regulating insulin secretion (Yukari Date et al., 2002). However, it was reported that 







1.3.5 Ghrelin Signaling Pathway 
Ghrelin was found to stimulate the pituitary gland to release GH differently 
than GHRH. Binding of ghrelin to its receptor leads to the activation of 
phospholipase C1 which in turn leads to an increase in intracellular Ca
2+
 level via 
inositol 1,4,5-triphosphate (IP3) signal transduction and diacylglycerol (Figure 14) 
(Malagón et al., 2003).  
 
Figure 14: Signaling pathway of ghrelin-inducing GH release. 
“Reproduced and edited (Camiña et al., 2003)”. 
 
The orexigenic effect of ghrelin is mediated by raising [Ca
2+
]i via adenosine 
monophosphate-activated protein kinase (AMPK) in neuropeptide Y (NPY) (Kohno, 
Sone, Minokoshi, & Yada, 2008) and agouti-related peptide (AgRP) neurons in the 
hypothalamus (Figure 15) (Seoane et al., 2003). 
Another way for ghrelin to exert its orexigenic effect is by triggering AMPK 






which is known to have an anorexigenic effect aside from being one of the major 
mediators in insulin signaling pathway (Figure 15) (Martin et al., 2007; Veilleux, 
Houde, Bellmann, & Marette, 2010). 
 
Figure 15: Signaling pathway of ghrelin-inducing food intake in the hypothalamus. 
“Modified from Hindawi Publishing Corporation, Scientifica” (Delporte, 2013) 
 
The vagus nerve was shown to mediate ghrelin effects by transmitting its 
signals to the brain (Yukari Date, 2012), aside from ghrelin’s own autocrine, 
endocrine and paracrine effects (Avau et al., 2013; De Vriese, Grégoire, De Neef, 







1.3.6 Effect of Ghrelin on Food Intake 
Plasma ghrelin level have been shown to increase during fasting and before 
meals and decrease after meal, yet in obese humans, ghrelin was not suppressed 
after food consumption (English, Ghatei, Malik, Bloom, & Wilding, 2002).  
Ghrelin level was also shown to differ dramatically when equal amounts of 
calories were served from sugar, protein and fat (Beck, Musse, & Stricker-Krongrad, 
2002). 
Centrally administered ghrelin led to a significant increase in food 
consumption (Lawrence, Snape, Baudoin, & Luckman, 2002) and  NPY and AgRP 
expression (Goto et al., 2006; Kamegai et al., 2000) independently from its GH 
releasing effect (Kamegai et al., 2001; M. Nakazato et al., 2001; M. Tschöp, Smiley, 
& Heiman, 2000). Ghrelin also stimulates growth hormone releasing hormone 
directly to alter feeding activity (Osterstock et al., 2010).  
Ghrelin is thought to play a role in meal initiation (D. E. Cummings et al., 
2001; Sugino et al., 2002), while lacking ghrelin receptor led to less food 
consumption (Zigman et al., 2005).  
Patients with bulimia nervosa, an eating disorder showed no difference in 
ghrelin serum level than the their aged-matched controls (Michiko Nakazato et al., 
2004). 
1.3.7 Effect of Ghrelin on Body Weight and Obesity 
The dramatic increase in the prevalence of obesity and its consequent 
metabolic complications is becoming a burden and a threat to health and life span of 






In obese people circulating ghrelin level decrease (Matthias Tschöp et al., 
2001) and correlate negatively with body mass index (BMI) (Shiiya et al., 2002). 
Moreover, body weight loss is associated with elevated circulating ghrelin level 
(Hansen et al., 2002) implying the possibility of recruiting ghrelin to be used as a 
preventive measure to curb the obesity rise. 
Whereas, administration of ghrelin caused weight gain (M. Tschöp et al., 
2000), in a dose-dependent manner (Matthias Tschöp, Statnick, Suter, & Heiman, 
2002), a study showed that absence of GHS-R1a can protect against developing diet-
induced obesity, indicating a direct effect of ghrelin on body weight (Zigman et al., 
2005). 
1.3.8 Ghrelin and Pancreatic Islet Cells and its Association with Islet Cells 
Hormones 
Ghrelin is expressed in pancreatic tissue along with its receptor (Volante et 
al., 2002) and interestingly fetal pancreas highly expresses ghrelin than fetal 
stomach in the first two weeks postnatal life (Chanoine & Wong, 2004). However, 
ghrelin was also found to be secreted from the pancreas (Dezaki et al., 2006).  
1.3.8.1 Ghrelin and Insulin 
Ghrelin and insulin were found to react correspondingly with preprandial 
increase and postprandial decrease (D. E. Cummings et al., 2001; Shiiya et al., 
2002). Moreover, glucose-induced insulin secretion was enhanced by ghrelin 
infusion (Takahashi et al., 2006). 
In vitro studies have shown that ghrelin induces insulin secretion differently 
in normal and in diabetic pancreas (E. Adeghate & Ponery, 2002) and that ghrelin 






Cour, Håkanson, & Lundquist, 2004). In another study, ghrelin failed to stimulate 
basal insulin release or to increase cytosolic free calcium concentration in rat β cells 
in the presence of 2.8 mmol/l glucose, which is contradictory to its effect at 8.2 
mmol/l glucose level (Yukari Date et al., 2002). In a study done by Dezaki K et al, 
(2011), ghrelin suppresses glucose-induced insulin release via attenuating cAMP 
pathway in β cells (Figure 16) (Dezaki et al., 2011; Wang et al., 2010). Additionally, 
ghrelin was found to influence glucose homeostasis through its effect on insulin 
secretion and insulin receptor signaling (Yada et al., 2014). 
 
Figure 16: Ghrelin signaling in islet β cells. 
“Reproduced and edited (Yada et al., 2014)”. 
1.3.8.2  Ghrelin and Other Islets Hormones  
Ghrelin co-localized with glucagon in pancreatic α cells (Yukari Date et al., 
2002). However, a study showed that ghrelin is synthesized and secreted from α 
cells (Kageyama et al., 2005a). Another study showed that ghrelin induces glucagon 






2002), which might be in part mediated by neuronal constitutive nitric oxide 
synthase (Qader, Lundquist, Ekelund, Håkanson, & Salehi, 2005). 
Ghrelin was found to significantly increase the circulating levels of  both 
somatostatin and pancreatic polypeptide in human (Arosio et al., 2003). Whereas, 
somatostatin suppresses ghrelin secretion from the stomach (Shimada et al., 2003), 
and reduces circulating ghrelin level independently of GH status (Nørrelund et al., 
2002). 
1.3.9 Ghrelin Effect on Diabetes Mellitus 
Ghrelin was implicated in the development of insulin resistance (Zhang et 
al., 2013) and β cell insufficiency (Lin, Chen, Lin, & Duan, 2009) in T2DM 
(Pöykkö et al., 2003). Independently from the sedentary life style and obesity, 
ghrelin level were found to be reduced in T2DM patients and in insulin-resistant 
obese adults (McLaughlin, Abbasi, Lamendola, Frayo, & Cummings, 2004), while 
in T2DM women aerobic exercise with the absence of substantial body weight loss 
influenced ghrelin level positively (Kadoglou et al., 2012). Furthermore, treatment 
of T2DM with metformin raised plasma ghrelin level (Doogue et al., 2009) and 
postprandial fall in ghrelin concentrations was prolonged (English et al., 2007).  
1.3.10 Other Functions and Role of Ghrelin in Different Tissues 
Ghrelin plays a role in many systems (Figure 17). For example, in the 
gastrointestinal system, ghrelin acts by increasing gastric acid secretion and 
stimulating gastric motility (Y. Date et al., 2001; Masuda et al., 2000). In the 
cardiovascular system, ghrelin has potent cardioprotective actions (Nagaya & 
Kangawa, 2004) where it plays a role in preventing heart failure (Yang, Liu, Liu, & 






2014).Plasma ghrelin was found to be elevated in advanced renal failure (Tritos, 
Kissinger, Manning, & Danias, 2004), yet it decreases significantly in advanced 
cancer (Legakis, Stathopoulos, Matzouridis, & Stathopoulos, 2009). 
Additionally, ghrelin is thought to be involved in the growth and progression 
of tumors (Omoto et al., 2014), whereas ghrelin variants (In1-ghrelin, which lacks 
exon 3-4) have been detected in human breast cancer tissue (Gahete et al., 2011). 
Ghrelin and ghrelin receptor were also highly expressed in prostate cancer 
(Lanfranco et al., 2008).  
Ghrelin is involved in many other biological functions like learning (Bellar, 
Glickman, Judge, & Gunstad, 2013; E. Li et al., 2013; Tóth, László, & Lénárd, 
2010; Zhu et al., 2013), memory (Goshadrou, Kermani, Ronaghi, & Sajjadi, 2013; 
Zhao et al., 2014), sleeping (Al-Disi et al., 2010; Figueiro, Plitnick, & Rea, 2012; 
García-García, Juárez-Aguilar, Santiago-García, & Cardinali, 2014; Steiger, Dresler, 
Schüssler, & Kluge, 2011), depression (Ozsoy, Besirli, Abdulrezzak, & Basturk, 
2014; Poretti et al., 2015) and behavior (Carlini et al., 2002; Gastón, Schiöth, De 







Figure 17: Physiological action of ghrelin. 







1.4 Streptozotocin and its Diabetogenic Effects 
Streptozotocin (STZ) is an antibiotic used in chemotherapy an alkylating 
agent in the treatment of metastatic cancer of the pancreatic islet cells. In 1963 it 
was reported that STZ is diabetogenic. Ever since STZ has been used by many 
researchers to induce experimental models of DM. STZ is known to be particularly 
toxic to insulin-secreting β cells in the pancreas. Due its chemical structure which is 
similar to glucose, STZ is easily transported into the cell by the glucose transport 
protein GLUT2 (Akbarzadeh et al., 2007; Damasceno et al., 2014; Lenzen, 2008; 
Szkudelski, 2001). 
Figure 18, describes the mechanism of action by which STZ induces DM. In 
β cells STZ causes alkylation of DNA which will induce activation of poly ADP-
ribosylation, a process known to be more important for the diabetogenicity of STZ. 
Poly ADP-ribosylation leads to cellular NAD
+
 and ATP depletion which will 
provide a substrate for xanthine oxidase resulting in the formation of superoxide 
radicals. Consequently, hydrogen peroxide and hydroxyl radicals are also generated. 
STZ will also release nitric oxide leading to inhibition of aconitase activity and 
finally participates in DNA damage. As a result β cells will be destroyed by necrosis 







Figure 18: Streptozotocin mechanism in inducing diabetes mellitus. 
















Chapter 2: Hypothesis, Aims and Objectives 
 
In literature, ghrelin was not only reported to be expressed in the pancreas 
but also to be secreted from it. Based on this we hypothesized that ghrelin co-
localizes with insulin-secretin β cells of the pancreatic islet of Langerhans and that it 
increases insulin secretion which will result in subsequent low level of glucose in 
the blood. We also hypothesized that ghrelin can prevent or delay the onset of DM. 
The primary focus of this study was to investigate the effect of ghrelin 
treatment on fasting blood glucose, body weight, insulin secretion and liver 
functions in normal and STZ-diabetic compared to age-matched control rats. We 
also examined the pattern of distribution and co-localization of ghrelin in the 
pancreatic islet of Langerhans. 
Specific objectives of the study are: 
1. To study the effect of chronic ghrelin treatment on fasting blood 
glucose level, body weight, glucose handling and insulin secretion in 
ghrelin-treated rats in comparison to age-matched controls. 
2. To examine the distribution pattern and co-localization of ghrelin 
with insulin and glucagon in pancreatic islet cells. 
3. To investigate the co-localization of ghrelin and insulin in secretory 








Chapter 3: Materials and Methods 
 
3.1 Animal Models 
Male Wistar rats aged 7–8 weeks and weighing 200 – 300 g were used in this 
study. All rats were acquired from the College of Medicine and Health Sciences, 
United Arab Emirates University. Rats were housed in the Animal House Facility 
which was maintained at 22-25 °C, along with a 12 hours light/dark cycle. A 
standard pellet diet with tap water was provided ad libitum. Diabetic rats were kept 
in metal cages and normal (non-diabetic) rats were kept in regular polycarbonate 
cages with wood chips bedding. 
3.2 Induction of Experimental Diabetes Using Streptozotocin 
Streptozotocin (STZ) was used to induce diabetes in rats by a single 
intraperitoneal injection at a dose of 60 mg/kg body weight (Akbarzadeh et al., 
2007). STZ was freshly prepared by dissolving it in citrate buffer (0.5M, pH 4.5). 
Rats were considered diabetic if their fasting blood glucose level were above 126 
mg/dl. 
3.3 Experimental Design 
As shown in Figure 18, the rats were divided into two groups: normal and 
diabetic. Diabetic group received intraperitoneal injection of freshly prepared STZ 
(section 2.2) to induce DM. Two days after STZ injection, fasting blood glucose 
(FBG) level was measured and rats having FGB level less than 126 mg/dL were 
discarded from the study. The two main groups were further subdivided into another 






5 μg/kg body weight of ghrelin “as treated”. Both normal saline and ghrelin were 
injected intraperitoneally on a daily basis and for duration of four weeks. At the end 
of the fourth week, all rats were sacrificed except some rats from normal treated 
group that were subjected to STZ injection to induce diabetes after one week from 
stopping ghrelin treatment; in order to investigate the ability of ghrelin to prevent or 
delay the onset of DM. FBG and body weight were measured after one week of STZ 
injection (Figure 19). 
 
 







Figure 20: Schematic drawing explaining the study design of pre-diabetic ghrelin-
treated group. 
 
3.4 Fasting Blood Glucose and Body Weight Measurements 
Body weight was measured once weekly along with FBG level. Animals 
were fasted for 12 hours and blood samples were collected from the tail vein in 
order to measure FBG using OneTouch® Ultra®2 Glucometer (LifeScan, Inc., 
Milpitas, CA, USA). 
3.5 Glucose Tolerance Test  
Glucose tolerance test (GTT) was performed at the end of the experiment 
(four weeks, except pre-diabetic ghrelin-treated group where it was performed after 
six weeks). Rats were fasted overnight (12 hours) and each rat received an 
intraperitoneal injection of 10 mg/kg/wt glucose. Blood samples were collected from 
the tail vein of the rats and blood glucose level was measured at 0 and 30, 60, 120 






3.6 Blood and Tissue Collection 
After the GTT, all rats were anesthetized with ether. A clean incision through 
the abdominal wall was made to expose the organ of interest. Blood was obtained 
from the inferior vena cava and kept in two separate tubes (yellow top: gel tube that 
helps splitting the serum from the rest of the blood sample components, purple top: 
contain EDTA). 
Pancreatic tissue was collected from all the animals and cut into two parts: 
one part for immunohistochemistry and immunofluorescence studies and the second 
for electron microscopy. 
3.7 Tissue Processing 
Pancreatic tissues were embedded in Zamboni’s fixative for overnight 
fixation prior to immunohistochemistry and immunofluorescence studies using light 
microscopy. However, for electron microscopy, pancreatic tissues were fixed 
overnight in McDowell solution. 
3.7.1 Tissue Processing for Immunohistochemistry and Immunofluorescence 
Study 
After overnight fixation in Zamboni’s fixative pancreatic tissues were 
dehydrated in a series of graded ethanol concentrations ascending from 70% to 95% 
and “two changes” in 100% ethanol for a minimum of 2 hours per step. Specimens 
were then exposed to xylene “two changes” and subsequently paraffin wax at 55 °C 
(three changes). Tissues were embedded in paraffin blocks and sections of 6 µm 
thickness were sliced using a microtome (Shandon AS325, City, USA), and 






gelatin-coated slides, and kept on a hot plate to dry for a minimum of 2 hours to 
enhance the attachment of the sections. 
3.7.2 Tissue Processing for Electron Microscopy 
Some of the pancreatic tissues that were collected at the end of the 
experiment, were cut into small pieces, and immersed in McDowell’s fixative for 
overnight fixation at 4 °C after trimming off fats and connective tissue. The 
specimens were later washed three times with 0.1 phosphate buffer (15 minutes 
each) and post-fixed in 1% osmium tetroxide for one hour. The samples were then 
dehydrated in ascending concentrations of ethanol (30%, 50%, 70%, 95%, and 
100% “two changes”, 15 minutes each). Two changes of propylene oxide was used 
for clearing the specimens for 15 minutes each. The samples were then transferred 
and exposed to different ratios of propylene oxide and resin (1:1, 1:2 and 1:3) for 
one hour each before infiltration with pure resin for overnight at 4 °C. Specimens 
were embedded in the resin using molds and kept in the oven to polymerize for 
overnight at 60 °C. Blocks of resin were trimmed and 1µm semi-thin sections were 
cut using glass knives on the ultra-microtome. Sections were transferred into a drop 
of water on the microscope slides using watchmaker’s forceps and toluidine blue 
was used to stain the tissues. Toluidine blue-stained tissues were later examined 
with the microscope to locate the islets of Langerhans using light microscopy 
examination. Using a diamond knife, resin blocks were further trimmed for ultra-
thin sectioning and placed on copper grids using a wire loop. The girds were placed 







3.8 Immunohistochemistry Study: Avidin-Biotin Complex Staining Method 
for Paraffin Section 
Pancreatic tissues slides were rinsed for 5 minutes in xylene solution (two 
changes) to remove the paraffin wax, followed by rehydration step using a series of 
descending concentration of ethanol solution (100% ethanol “two changes, 5 
minutes each”, 95%, 70% and 50% “3 minutes each”), followed by washing with 
phosphate buffer solution (PBS) for 5 minutes before retrieval of antigen using 
citrate buffer (pH 6) treatment, where the slides were incubated for 1 min in the 
microwave using power 10, followed by 10 minutes incubation at power 1, and 
finally 20 minutes incubation at room temperature. The slides were washed with 
PBS (three changes, 5 minutes each) before marking the section with a Dako pen. 
Slides were incubated with 0.3% hydrogen peroxidase - methanol solution for 30 
minutes to block endogenous peroxidase activity. The tissue sections were blocked 
using protein block for 45 minutes at room temperature, followed by overnight 
incubation with corresponding primary antibody (insulin anti-guinea pig or ghrelin 
anti-rabbit) at 4°C. Next day, the slides were kept at room temperature for an hour 
then washed with PBS (three changes, 5 minutes each), followed by incubation with 
the secondary biotinylated antibody (anti-guinea pig IgG for insulin and anti-rabbit 
IgG for ghrelin) at room temperature for 1 hour. The secondary antibody was 
washed off with PBS (three changes, for 5 minutes each), and the section were then 
incubated with streptavidin peroxidase conjugated for an hour. To reveal peroxidase 
activity, sections were washed with PBS (three changes) for 5 minutes each 
followed by 3,3-diaminobenzidine tetrahydrochloride DAB (Sigma) in PBS 






Finally, the sections were washed for 5 minutes using distilled water and 
dehydrated in a series of ascending concentration of ethanol 50%, 70%, 95% and 
100% (two changes) followed by xylene (two changes) for 5 minutes each. The 
slides were finally mounted with DPX . AxioCam HRc digital camera with 
AxioVision 3.0 software was used to capture images of stained sections (Carl Zeiss, 
Oberkochen, Germany). Images were then adjusted for contrast and brightness using 
image J 1.47V. 
3.9 Double Labeling Immunofluorescence Staining Method for Paraffin 
Sections 
Sections of pancreas, 6 µm thickness, were immersed twice in xylene for 5 
minutes at room temperature to remove paraffin wax followed by rehydration in 
descending concentrations of ethanol for 3 minutes each. Slides were then incubated 
for 5 minutes in distilled water before treating the slides with citrate buffer for 
antigen retrieval in the microwave as described previously in section 2.8. Slides 
were then washed three times in PBS after marking the sections of interest with a 
Dako pen. Slides were incubated first with the blocking reagent at room temperature 
for 45 minutes followed by an overnight incubation with primary antibody (Table 2) 
(insulin anti-guinea pig, ghrelin anti-rabbit/ anti mouse and glucagon anti-mouse) at 
4 °C. On next day, the slides were incubated at room temperature for one hour 
followed by PBS wash (three changes, for 5 minutes each) followed by one hour 
incubation at room temperature with the secondary antibody (ghrelin: anti-rabbit / 
anti-mouse RRX, insulin: anti-guinea pig FITC and glucagon: anti-mouse FITC) 
(Table 3). Finally slides were washed with PBS (three changes, 5 minutes each) 






fluorescence microscopy. Sections were examined using AxioCam HRc digital 
camera with AxioVision 3.0 software (Carl Zeiss, Oberkochen, Germany) fixed with 
z-plane fluorescence. Sections contrast and brightness were adjusted images were 
merged using image J 1.47V. 
 
Table 3: List of names and dilutions of the primary and secondary antibodies used in 
this study 
3.10 Transmission Electron Microscopy Post-embedding Immunogold Double 
Labeling Protocol 
All grids were jet-washed with deionized water (5 mL each), and were 
incubated with 25 µL of 10% H2O2 in water for 10 minutes. Grids were again 
washed with deionized water and immersed in 0.5 M NH4Cl in 0.01 M PBS (pH 7.3) 
for 20 minutes before washing them again with PBS ‘washing buffer’ (1% BSA and 
0.1% Tween-20). 
Tissues were blocked by 20% normal goat serum (NGS) diluted in washing 
buffer ‘blocking buffer’ for 10 minutes followed by overnight incubation at 4 °C 
with primary antibody (Ghrelin anti-rabbit 1:100 diluted in PBS, pH 7.3, containing 






temperature for an hour before washing them with PBS three times and again 
blocking buffer incubation at room temperature for 20 minutes. Grids were further 
incubated in goat anti-rabbit IgG conjugated to 15 nm gold particles (diluted 1:20 in 
antibody buffer) at room temperature for two hours. 
Grids were rinsed again with PBS three times before repeating the whole 
process again but with insulin as second primary antibody (insulin anti-mouse 
(1:100) diluted in antibody buffer (PBS, pH 7.3, containing 1% BSA, 0.1% Tween-
20 and 5% NGS)) which was labeled with 5 nm gold particles diluted (1:20 in 
antibody buffer) at room temperature for two hours before fixing the grids with 
glutaraldehyde (2.5% aqueous) for 5 minutes, then washing with deionized water 
and left on filter paper to dry for one hour. Contrasting the grids was done with 
uranyl acetate and lead citrate for 15 and 7 minutes, respectively. They were later 
washed with deionized water full 10 mL syringes each before leaving the grids to 
dry on filter paper. The sections were later viewed with a Philips TEM. 
3.11 Enzyme-Linked Immunosorbent Assay  
For the quantitative determination of insulin in serum samples, Enzyme-
Linked Immunosorbent Assay (ELISA) was performed using Mercodia 
Ultrasensitive Rat Insulin ELISA kit and protocol as shown in Figure 21.  
In wells 25 μL of Calibrators (standers, 0, ...,6) were added, 25 μL of 
samples were added in the rest of the wells followed by the addition of 100 μL of 
enzyme conjugate 1X solution into each well, then the plate was incubated in the 
shaker (700-900 rpm) for 2 hours at room temperature (18-25°C). Later on, the plate 
was wash 6 times with 700 µL wash buffer 1X solution per well using an automatic 






added to each well and discarded. Finally, 200 μL Substrate TMB was added into 
each well and was incubate 15 minutes at room temperature (18-25°C) before 
adding 50 μL Stop Solution to each well. The plate was placed on the shaker for 
approximately 5 seconds to ensure mixing and then the results were read by 
Mercodia software using optical density of 450 nm. 
 






3.12 Biochemical Analysis  
Serum samples was used to detect the levels of Alanine Aminotransferase 
(ALT) and Aspartate transaminase (AST) using a Beckman Coulter Synchron Lx20 
PRO clinical system at Al Qatara Veterinary Laboratory. 
3.13 Statistical Analysis  
Statistical analysis was performed using GraphPad Prism version 5.01. Data 
were presented as mean ± Standard Deviation (SD). p<0.05 were considered to be 
statistically significant. One-way ANOVA was used between experimental groups 
and corresponding control groups, followed by post-hoc Bonferroni. Unpaired t-test 
was used to analyze the significance of differences between mean values within the 







Chapter 4: Results 
 
4.1 Effect of Ghrelin Treatment on Fasting Blood Glucose Level of Normal 
and Diabetic Wistar Rats 
Figure 22 shows the effect of ghrelin treatment on fasting blood glucose 
level of normal and diabetic rats compared to normal saline treatment in control 
groups. Ghrelin treatment did not appear to have an influence on fasting blood 
glucose of normal treated rats when compared to normal control. Despite the slight 
elevation in fasting blood glucose level of diabetic rats treated with ghrelin after two 
weeks from the beginning of the treatment, this group showed lower fasting blood 
glucose level when compared to diabetic control group treated with normal saline at 
week three and four. 
 
Figure 22: Effect of ghrelin treatment on fasting blood glucose level of normal and 
diabetic wistar rats. 
 Fasting blood glucose level (mg/dL) in normal and diabetic rats treated with either 
ghrelin or normal saline (NS), during a course of four weeks treatment. (n=4-7). 






4.2  Effect of Ghrelin Treatment on Body Weight of Normal and Diabetic 
Wistar Rats 
Figure 23 shows the effect of ghrelin treatment on body weight of normal 
and diabetic rats in comparison to age-matched controls treated with normal saline. 
After two weeks from the beginning of the treatment, normal and diabetic 
groups treated with ghrelin had higher body weight than other rats treated with 
normal saline. However, after four weeks, ghrelin-treated rats showed lower body 
weight than their corresponding controls.  
 
Figure 23: Effect of ghrelin treatment on body weight of normal and diabetic wistar 
rats. 
Body weight (g) in normal and diabetic rats treated with either ghrelin or normal 
saline (NS), during a course of four weeks treatment. (n=3-7). Results are expressed 







4.3 The Effect of Four Weeks of Ghrelin Treatment on Preventing or 
Delaying the Onset of STZ-induced Diabetes Mellitus in Wistar Rats 
Figure 24 shows the effect of ghrelin treatment before and after the induction 
of DM on fasting blood glucose level and body weight. Body weight (red line) was 
increasing upon ghrelin treatment, while fasting blood glucose level (blue line) was 
maintained within the normal range. Ghrelin treatment was stopped after four 
weeks. The rats received a single intraperitoneal STZ injection to chemically induce 
diabetes on week after stopping ghrelin treatment. One week from STZ injection, 
body weight showed a significant reduction, whereas fasting blood glucose level 
was increased significantly. 
 
Figure 24: The effect of four weeks of ghrelin treatment on preventing or delaying 
the onset of STZ-induced diabetes mellitus in wistar rats. 
Fasting blood glucose level “mg/dL” (blue line) and body weight “g” (red line) in 
normal rats treated with ghrelin before the administration of STZ to chemically 
induce DM in the fifth week of the study (arrow). (n=7). Results are expressed as 






4.4 The Effect of Ghrelin Treatment on Glucose Tolerance Test  
Figure 25 shows blood glucose values after glucose challenge in normal and 
diabetic rats treated with ghrelin compared to age-matched controls treated with 
normal saline. 
Ghrelin treatment showed no effect on the acute elevation of blood glucose 
level in normal group compared to NS treatment in normal control. On the other 
hand, though it is not statistically significant (p>0.05), diabetic rats treated with 
ghrelin exhibited a slight improvement in responding to glucose challenge when 
compared to diabetic rats treated with normal saline at 60 and 120 minutes after 
glucose load. 
Furthermore, despite the fact that pre-diabetic ghrelin-treated group showed 
elevated blood glucose baseline when compared to the other two diabetic groups 
which can be explained by the new onset of diabetes, the group handled glucose 
challenge well at 120 minutes after glucose loading. 
 
Figure 25: The effect of ghrelin treatment on glucose tolerance test. 
Intraperitoneal glucose tolerance in normal and diabetic groups treated with either 
ghrelin (before and after diabetes onset) or normal saline (NS), after a course of four 






4.5 Summary and Discussion – I 
 Although it was not statistically significant, but four weeks of ghrelin 
treatment succeeded in lowering fasting blood glucose level slightly in diabetic 
group. 
 No differences in the body weight were observed between ghrelin-
treated rats and their age-matched controls treated with normal saline. 
 Pretreatment of rats with ghrelin did not prevent nor delay the onset 
of diabetes mellitus. 
 Diabetic rats treated with ghrelin whether before or after the onset of 
DM showed better glucose handling when compared with diabetic rats treated 
with normal saline. 
The above outcomes of ghrelin treatment seem promising and might be 
enhanced if one (or all) of the parameters of this study changed. For example 
increasing the dose of ghrelin for instance can result in either significant reduction 
of fasting blood glucose level or in increasing the body weight since many 
researches showed that the biological effects of ghrelin are dose-dependent 
(Akamizu et al., 2004; Carlini et al., 2002; Saito et al., 2005; ThidarMyint, Yoshida, 
Ito, & Kuwayama, 2006). Longer duration of ghrelin treatment may also yield a 
better outcome in diabetic rats. 
Since it has been reported that pancreatic cells express ghrelin receptor  
(Andralojc et al., 2009b; Chanoine & Wong, 2004; Kageyama et al., 2005b) and that 
the pancreas can also secrete ghrelin (Dezaki et al., 2006), coupled with the findings 
of this study, we decided to further study the pattern of distribution in the rat 







4.6 Immunohistochemical Localization of Insulin and Ghrelin in Normal 
and Diabetic Rat Pancreas 
4.6.1 Insulin 
Figure 26 shows the distribution pattern of insulin-secreting cells in the 
pancreatic tissue of normal control (A), normal treated (B), diabetic control (C) 
diabetic treated (D) and pre-diabetic ghrelin-treated (E) rats.  
Figure 26 shows insulin-immunopositive cells (black arrows) in the central 
and peripheral regions of the islets of normal control rats (A). Whereas in normal 
rats treated with ghrelin, this pattern is slightly disrupted (B) and insulin-
immunopositive cells (black arrows) are shown to be predominant in the central 
region of the islet. In diabetic control group insulin-immunopositive cells are hardly 
seen in the islet (C) as a result of STZ selective destruction to insulin-secretin β cells 
(Szkudelski, 2001). 
On the other hand, a higher number of insulin-immunopositive cells (black 
arrows) can be observed randomly in both the center and peripheral regions of islet 











Figure 26 also shows the pattern of distribution of ghrelin-containing cells in 
the pancreatic tissue of normal control (F), normal treated (G), diabetic control (H) 
diabetic treated (I) and pre-diabetic ghrelin-treated (J) rats.  
In normal control rats (F), ghrelin-containing cells (black arrows) are 
observed in the central and peripheral regions of pancreatic islets where insulin-
secreting cells are usually found. 
Whereas, in normal rats treated with ghrelin (G) the distribution pattern of 
ghrelin-immunopositive cells (black arrows) was found to be disrupted as insulin-
immunopositive cells of the same group (B). 
It was noticed that not only the number of insulin-secreting cells are affected 
by DM (C), but also the number of ghrelin-containing cells (H) which appear to be 
reduced when compared to normal control (F). 
Diabetic group treated with ghrelin (I) showed a well preserved distribution 
pattern of ghrelin-containing cells (black arrow) in normal control (F). While 
ghrelin-immunopositive cells (black arrow) are randomly distributed in the 
pancreatic islet of pre-diabetic ghrelin-treated rats which is similar to what was 








Figure 26: Immunohistochemical localization of insulin and ghrelin in normal and 
diabetic rat pancreas. 
Distribution pattern of insulin-secreting cells (A, B, C, D, and E) and ghrelin-
secreting cells (F, G, H, I, and J) in the pancreatic tissue.  Normal control (A and F), 
normal treated (B and G), diabetic control (C and H), diabetic treated (D and I) and 
pre-diabetic ghrelin-treated (E and J). Arrows shows insulin- and ghrelin-
immunopositive cells. Data are typical of those for 4 different animals in each 






In order to quantitative the results of ABC staining, both insulin- and 
ghrelin-immunopositive cells were counted in correlation to the total number of islet 
cells and presented as a percentage, as shown in Figure 27. 
In Figure 27-A, the percentage of ghrelin-immunopositive cells is the same 
in normal control and normal treated rats. On the other hand, a slight reduction is 
noticed in the percentage of ghrelin-immunopositive cells after the onset of DM, 
whereas diabetic treated and pre-diabetic treated groups displayed a higher 
percentage of ghrelin-positive cells when compared to diabetic control.  
The percentage of insulin-immunopositive cells shown in Figure 27-B is 
increased in normal treated compared to normal control rats. However, in diabetic 
control the percentage of insulin-containing cells showed dramatic reduction 
compared to normal control. Moreover, ghrelin treatment in diabetic and pre-
diabetic groups resulted in significant increase in insulin-immunopositive cells, 50% 








Figure 27: Percentage of insulin- and ghrelin-immunopositive cells. 
The relative-percentage of ghrelin-immunopositive cells (green bars) and insulin-
immunopositive cells (purple bars) in ghrelin treated normal and diabetic groups and 
their age-matched controls to total islet cells number. Results are expressed as mean 











4.7 Summary and Discussion – II 
 Ghrelin-immunopositive cells in the pancreas share the same 
distribution pattern with insulin-secreting cells in normal and diabetic groups. 
 The distribution pattern of insulin- and ghrelin-containing cells in the 
pancreatic islet was shown to be disrupted by the onset of DM in diabetic control 
rats and by ghrelin treatment in normal treated rats. 
 Ghrelin treatment increased the number of insulin-containing cells 
significantly in both diabetic and in pre-diabetic groups. 
 The percentages of insulin- and ghrelin-immunopositive cells in the 
pancreatic tissue of diabetic control rats were shown to decrease. 
Ghrelin treatment rescued the insulin-secreting cells from STZ selective 
destruction in diabetic rats. While in the normal treated group, ghrelin treatment 
appears to enhance either the proliferation or the differentiation of insulin-secreting 
cells which resulted in a higher percentage of those cells. 
Although ghrelin cells in the pancreas (epsilon cells) have been reported to 
represent about 1% of total islet cells, our study showed that the percentage of 
ghrelin-immunopositive cells is higher in all groups. This indicates that ghrelin is 
expressed by other types of cells in the islet. Moreover, inducing DM via STZ 
resulted not only in reducing insulin-immunopositive cells but also ghrelin-
immunopositive cells which led to the assumption that either epsilon cells are also 
sensitive to STZ or that some of the β cells that were destroyed contained both 
insulin and ghrelin.  
The significant increase in number of insulin-secreting cells observed in this 
study has prompted us to perform further experiments to determining serum insulin 






4.8 Effect of Ghrelin on Serum Insulin Level 
Figure 28, shows serum insulin level in normal, diabetic and ghrelin-treated 
rats using Mercodia Ultrasensitive Rat Insulin ELISA kit. A clear elevation in serum 
level of insulin was observed in all ghrelin-treated groups in comparison to their 
corresponding controls. A significant (p <0.02) decrease in serum insulin level of 
diabetic control rats was observed when compared to normal control rats. 
Furthermore, normal ghrelin-treated rats showed significant (p < 0.04) increase in 
insulin level compared to their age-matched control. Moreover, ghrelin treatment 
increased serum insulin level in diabetic groups compared to diabetic control; 
however it was significant only in pre-diabetic ghrelin-treated group. 
 
Figure 28: Effect of ghrelin on serum insulin level. 
Quantitative determination of insulin level in the serum of normal and diabetic 
groups treated with either ghrelin (before and after diabetes onset) or normal saline 
(NS), for a course of four weeks. (n =4-7). Results are expressed as mean ± S.D. * p 






4.9 Summary and Discussion – III 
 Ghrelin treatment increased insulin secretion in normal and diabetic 
groups of rats. 
 Despite the new onset of DM in pre-diabetic treated group, ghrelin 
pre-treatment showed significant increase in the serum insulin level. 
This result suggests that ghrelin treatment did not only increase the 
percentage of insulin-secreting cells significantly in diabetic groups (Figure 27) but 
also enhanced their secretory function which resulted in increasing serum insulin 
level (Figure 28). This suggests that ghrelin treatment rescued β cells from 
destruction by STZ. 
Moreover, ghrelin treatment impact on insulin secretion can be recruited as a 
new approach in DM management to either reduce insulin dose or delay insulin 












4.9.1 Co-Localization of Ghrelin with Insulin and Glucagon in Pancreatic 
Islet Cells 
4.9.1.1 Ghrelin and Insulin 
Figure 29 shows ghrelin-containing cells (A) and insulin-containing cells (B) 
and the co-localization of ghrelin with insulin (C).  
It is clearly shown that in normal control rats, ghrelin localizes in both the 
central and peripheral portions of the islet where insulin-secreting cells are usually 
found. Merging of the two figures shows that ghrelin is co-localized with insulin 
(white arrows). 
In normal ghrelin-treated group, ghrelin-positive cells are observed to 
concentrate in the periphery where glucagon secreting cells are found, however few 
cells showed co-localization of ghrelin with insulin. 
In diabetic groups, ghrelin-positive cells appear numerous in the pancreatic 
islet, in contrast to insulin-positive cells which are observed to be fewer. Moreover, 
the distribution pattern of insulin secreting cells is disrupted due to DM. On the 
other hand, ghrelin-positive cells localize mainly in the central portion of the 
pancreatic islet. On merging, very few cells showed co-localization between ghrelin 
and insulin (white arrows). 
It is noteworthy that in diabetic and pre-diabetic rats treated with ghrelin, 
insulin secreting cells were shown to be increased in number compared to diabetic 








Figure 29: Co-localization of ghrelin with insulin in pancreatic islet cells. 
Ghrelin-containing cells (A), Insulin-containing cells (B) and the merged image (C) 






4.9.1.2 Ghrelin and Glucagon 
Figure 30 shows ghrelin-containing cells (A) and glucagon-containing cells 
(B) and the co-localization of ghrelin with glucagon (C).  
In the pancreatic islet of normal control rats, ghrelin is observed to localize 
in the central as well as the peripheral portions, whereas, glucagon is seen primarily 
in the peripheral region. On merging, ghrelin was observed to co-localize with 
glucagon (white arrow); however, many ghrelin-immunoreative cells do not contain 
glucagon. 
Moreover, ghrelin was found to concentrate in the periphery of the 
pancreatic islet of normal ghrelin-treated group which resulted in a predominant co-
localization of ghrelin with glucagon (white arrow). 
Figure 30 also shows that ghrelin co-localizes predominantly with glucagon 














Figure 30: Co-localization of ghrelin with glucagon in pancreatic islet cells. 
Ghrelin-containing cells (A), Insulin-containing cells (B) and the merged image (C) 






4.9.2 Localization of Ghrelin and Insulin in the Secretory Granules of 
Pancreatic β Cells 
4.9.2.1 Wistar Normal Control Rat 
In Figure 31, shows the localization of ghrelin and insulin in β cells secretory 
granules in normal control group. 
The majority of secretory granules contain insulin (solid arrow) alone, 
whereas ghrelin (dashed arrow) is observed alone in some. Moreover, ghrelin and 
insulin where found to share the same secretory granules in normal control 
(circle). 
  
Figure 31: Localization of ghrelin and insulin in the secretory granules of pancreatic 
β cells of normal control rats. 
Electron micrograph showing immunogold labeling of ghrelin (15 nm gold particles) 
and insulin (5 nm gold particles) in the secretory granules of normal control Wistar 
rats. Ghrelin (dashed arrow) and insulin (solid arrow) in the secretory granules 
(circle). Magnification: X27500. 
Secretory granules 








4.9.2.2 Wistar Normal Treated Rat 
Figure 32, shows the localization of ghrelin and insulin in β cells secretory 
granules in normal ghrelin-treated group. 
Most of the secretory granules of pancreatic β cells contain ghrelin (dashed 
arrow) in contrast to normal control group (Figure 31). Furthermore, many secretory 
granules are found to contain both ghrelin and insulin (circle). 
  
Figure 32: Localization of ghrelin and insulin in the secretory granules of pancreatic 
β cells of normal ghrelin-treated rats. 
Electron micrograph showing immunogold labeling of ghrelin (15 nm gold particles) 
and insulin (5 nm gold particles) in the secretory granules of normal Wistar rats 
treated with ghrelin. Ghrelin (dashed arrow) and insulin (solid arrow) in the 













4.9.2.3 Wistar Diabetic Control Rat 
Figure 33 shows the localization of ghrelin and insulin in β cells secretory 
granules in diabetic control group. 
In diabetic control group, the secretory granules can be seen to reduce in 
number in diabetic control in comparison to normal control (31) as well as insulin- 
immunopositive gold-conjugates (solid arrow). In addition, ghrelin (dashed arrow) 
was found to co-localize with insulin in some of the secretory granules (circle).  
 
 
Figure 33: Localization of ghrelin and insulin in the secretory granules of pancreatic 
β cells of diabetic control rats. 
Electron micrograph showing immunogold labeling of ghrelin (15 nm gold particles) 
and insulin (5 nm gold particles) in the secretory granules of untreated diabetic rats. 









4.9.2.4 Wistar Diabetic Treated Rat 
Figure 34 shows the localization of ghrelin and insulin in β cells secretory 
granules in diabetic group treated with ghrelin. 
Ghrelin treatment resulted in increasing both ghrelin (dashed arrow) and 
insulin (solid arrow) in the diabetic group compared to their age-matched control 
(Figure 33). Moreover, ghrelin immunopositive gold-conjugates are seen to share 
secretory granules in pancreatic β cells with insulin (circle). 
 
 
Figure 34: Localization of ghrelin and insulin in the secretory granules of pancreatic 
β cells of diabetic ghrelin-treated rats. 
Electron micrograph showing immunogold labeling of ghrelin (15 nm gold particles) 
and insulin (5 nm gold particles) in the secretory granules of diabetic rats treated 
with ghrelin. Ghrelin (dashed arrow) and insulin (solid arrow) in the secretory 
granules (circle). Magnification: X27500. 
 









4.10 Summary and Discussion – IV 
 This study showed that ghrelin co-localizes with both insulin and 
glucagon. 
 We revealed that ghrelin co-localization pattern is disrupted after the 
onset of DM (diabetic control). 
 We demonstrated that ghrelin co-localizes with insulin in the 
secretory granules of pancreatic β cells. 
Investigating the co-localization of ghrelin and insulin in secretory granules 
of pancreatic β cells revealed that in ghrelin-treated groups both ghrelin and insulin 
immunopositive gold-conjugates were observed to be higher when compared to age-
matched controls.  
Furthermore, in ghrelin-treated group many secretory granules contain both 
ghrelin and insulin; whereas in normal and diabetic control groups few secretory 
granules were shown to contain both of them together.  
In addition, a previous study (Kageyama et al., 2005c) showed that GHS-R 
localizes with glucagon in the periphery of the islet. Also the same study showed 
that both ghrelin and GHS-R are located in the periphery of the pancreatic islets 
where glucagon cells are found. Along with the outcomes of this study, we 
concluded that ghrelin may enhance insulin secretion directly and also indirect 






4.11 Effect of Ghrelin Treatment on Liver Function 
4.11.1 Alanine Transaminase 
Figure 35, shows serum Alanine Transaminase (ALT) level in normal, 
diabetic and ghrelin-treated groups. 
The serum ALT level was elevated in control and ghrelin-treated groups. 
However, in diabetic groups treated with ghrelin, ALT level was further elevated. 
 
 
Figure 35: Serum Alanine Transaminase levels. 














Referencing Range 17.5 - 30.2 IU/l











4.11.2 Aspartate Transaminase  
Figure 36, shows serum Aspartate Transaminase (AST) level in normal, 
diabetic and ghrelin-treated groups.  
Serum AST level was also elevated in control groups as well as ghrelin-




Figure 36: Serum Aspartate Transaminase levels. 
Serum AST level of normal, diabetic and ghrelin-treated rats (ref. range: 45.7-80.8 














Referencing Range 45.7 - 80.8 IU/l











4.12 Summary and Discussion – VII 
In this study we tried to determine the effect of ghrelin chronic treatment on 
liver function by measuring the level of Alanine Transaminase (ALT) and AST in 
the blood serum of normal, diabetic and ghrelin-treated rats. 
ALT and AST are enzymes mainly found in liver, but also in small amount 
in the heart, pancreas, muscle and kidneys. Elevated level of ALT or AST or both 
indicates presence of liver damage. 
Control and ghrelin-treated groups showed elevated serum levels of ALT and 
AST. However, ghrelin treatment and pre-treatment in diabetic rats resulted in much 
higher levels of both enzymes than any other group which indicates liver damage.  
Our results of the harmful effect of ghrelin on liver correlate with De Vriese 
et al,  who suggested the involvement of ghrelin in the pathogenesis of liver diseases 
(Delhanty & van der Lely, 2013; Estep et al., 2011; Mykhalchyshyn, Kobyliak, & 
Bodnar, 2015).Furthermore, ghrelin was reported to modulate liver function 










Chapter 5: Summary  
 
 






Chapter 6: Discussion 
 
 Maintenance of glucose homeostasis is a very complicated process. 
Many neuroendocrine hormones are involved in regulating glucose uptake, 
storage and release. 
 Our results imply that ghrelin has an important role in glucose 
homeostasis which correspond to Heppner KM et al, report (Heppner, Müller, 
Tong, & Tschöp, 2012). However, the controversy about the exact effects of 
ghrelin on blood glucose level remain unresolved (Chabot, Caron, Laplante, & 
St-Pierre, 2014).  
 In literature, it was reported that ghrelin level correlates positively 
with insulin resistance (Purnell, Weigle, Breen, & Cummings, 2003). However 
Pöykkö SM et al, reported that in T2DM ghrelin concentration was negatively 
associated with insulin resistance (Pöykkö et al., 2003). However, in this study 
ghrelin-treated rats handled glucose challenge well indicating that ghrelin 
enhances tissues response to insulin. 
 Ghrelin is known as a “hunger hormone” (Higgins et al., 2007) and 
was reported to increase food consumption (Kamegai et al., 2001). Moreover, 
while many studies showed that ghrelin treatment positively induces weight gain 
(Salfen, Carroll, Keisler, & Strauch, 2004), a study on Japanese quail showed 
that the effect of ghrelin on food intake correlates negatively with the dose of 
ghrelin (Shousha et al., 2005). However our observation correlates with those of 
Gelling RW et al, which revealed that food intake of STZ-diabetic rats was 






measurement was taken to calculate the food consumption in this study and the 
reasons behind the slight reduction in the body weight are not clear. 
 Altering one or two or all of the treatment criteria such as dose, 
duration and frequency of the treatment, may further influence our outcomes. 
Moreover, the difference between our results and those available in the literature 
may be due to one of more of the factors outlined above.  
 We have demonstrated that the distribution pattern of ghrelin-
containing cells is similar to that of insulin-containing cells and that both 
patterns were disrupted after the onset of DM. Moreover, in a study investigating 
the cellular distribution of ghrelin in the pancreas of diabetic rats it was shown 
that DM is associated with a slight reduction in the expression of ghrelin in 
pancreatic islet cells (Yildirim, Sundler, & Bolkent, 2007). This observation 
corroborates data reported in our study. 
 We also revealed that ghrelin treatment and pre-treatment resulted in 
significant increase of insulin-containing cells. This finding is in agreement of 
that of Turk et al., who reported that the number of insulin-positive cells 
increase after the administration of 100 µg of ghrelin per day for four weeks 
(Turk, Dağistanli, Sacan, Yanardag, & Bolkent, 2012). 
 Moreover, ghrelin treatment resulted in elevated level of serum 
insulin, indicating the role of ghrelin in enhancing insulin secretion. This 
suggests the possibility of recruiting ghrelin as a potential therapeutic approach 
in the management of DM.  
 Additionally, ghrelin was observed to co-localize with both insulin 
and glucagon in pancreatic islet. The co-localization of ghrelin with insulin was 






However, ghrelin and glucagon co-localization was not affected in either 
diabetic control or normal ghrelin-treated groups. Ghrelin localization in 
pancreatic islet cells is controversial. Our observation implies that ghrelin 
predominantly co-localizes with glucagon in pancreatic islet, which corroborates 
with those of Date, et al. (Yukari Date et al., 2002), who showed that ghrelin is 
located in pancreatic α cells. However, another studies revealed that ghrelin co-
localizes with β cells (Volante et al., 2002), while some have even reported that 
ghrelin has its own cells (Wierup, Yang, McEvilly, Mulder, & Sundler, 2004). 
 Furthermore, our study demonstrated that ghrelin co-localizes with 
insulin in the secretory granules of pancreatic β. 
 Elevated serum levels of AST and ALT indicates liver injury (Nkosi, 
Opoku, & Terblanche, 2006; Senior, 2012). Moreover, it is known that the 
serum level of ALT increases after the onset of diabetes (Aragon & Younossi, 
2010). Our investigation of ghrelin effect on liver function revealed that in DM, 
ghrelin treatment increase AST and ALT enzymes indicating that ghrelin may be 







Chapter 7: Conclusion 
 
We addressed our hypothesis and demonstrated that ghrelin co-localizes with 
insulin-secreting β cells. We also revealed the involvement of ghrelin in insulin 
secretion and its effect on lowering blood glucose level. Unfortunately, ghrelin 
failed to prevent/delay DM which was the second hypothesis of this study.  
The outcomes of this investigation suggest that ghrelin can be a new 
approach in DM management (Figure 38). 
 
 






Chapter 8: Limitations and Future Prospective 
 
 The number of rats was low in some groups which resulted in higher 
Standard Deviation. 
 The duration of treatment was only four weeks and we studied only 
one dose, which is considered to be relatively low. 
 Our data represents the effect of ghrelin treatment in only one model 
of DM (T1DM). 
 We only studied the co-localization of ghrelin with insulin in 
pancreatic β cells secretory granules. The study of the co-localization of ghrelin 
with glucagon in the secretory granules of α cells is the next step; to address 
whether ghrelin influence on insulin secretion is a result of ghrelin hypothesized 
effect on glucagon secretion/inhibitory effect on insulin, in addition to 
measuring glucagon level in blood serum. 
 Studying the effect of ghrelin treatment at a younger age (birth!).  
 Determining the amount of food consumption and examining the 
effect of ghrelin on different caloric intake. 
 Finally, more investigations are required to examine the reason 
behind the slight reduction in body weight by studying the possibility of 
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